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Abstract 
In the post genomic era, metabolomics, as an integrated part of system biology, offers a promising 
approach to identify biomarkers associated with diseases and hence has been widely used in disease 
diagnosis, toxicology, plant science, and pharmaceutical and environmental research. Based on the 
specific study goals, metabolomics involves two major categories: targeted and untargeted. Unlike 
targeted metabolomics with well-established analysis method, untargeted metabolomics still needs to 
overcome some technical challenges. This dissertation attempts to address these challenges and to 
establish a feasible untargeted metabolomics platform from sample preparation to data interpretation 
and biologically meaningful validation. In this dissertation, gas chromatography-mass spectrometry 
(GC-MS) was used as the analytical instrument to detect and identify metabolites. This GC-MS based 
untargeted metabolomics was successfully applied to study four different aspects of glucose-
stimulated insulin secretion (GSIS), including the biochemical mechanism underlying insulin 
secretion, biphasic insulin secretion, time-dependent effects (TDE) of glucose on insulin secretion, as 
well as the role of alpha-ketoglutarate dependent hydroxylation in regulation of insulin secretion. 
GSIS was identified by orthogonal partial least squares (OPLS) to be associated with not only 
glycolysis and tricarboxylic acid cycle (TCA cycle), but also the pentose phosphate pathway (PPP), 
the sorbitol-aldose reductase pathway as well as aspartate. The characterization of the kinetics of 
insulin secretion revealed that alpha-ketoglutarate, succinate and hydroxyproline were the metabolites 
strongly associated with the second phase of biphasic insulin secretion. Study of TDE by using a 
metabolomics approach showed that the time-dependent inhibition (TDI) of glucose on insulin 
secretion is mainly regulated by redox state in pancreatic beta cells, since it was suggested to be 
correlated to the decreased ratio between dihydroxyacetone phosphate (DHAP) and alpha-
glycerolphosphate (alpha-GP). This was probably the result of the reduced malate-aspartate shuttle 
activity and lower lactate output in beta cells.  On the other hand, time-dependent potentiation (TDP) 
might be mediated by succinate-regulated pro-insulin biosynthesis. Finally, alpha-ketoglutarate 
dependent hydroxylation was found to be a master regulator that controls glucose metabolism as well 
as glucose derived anaplerosis, a finding which, if true, provides a positive feedback loop for the 
secretion function of pancreatic beta cells. Overall, this GC-MS based untargeted metabolomics 
approach was established and then was used to study the mechanism of GSIS. Alpha-ketoglutarate 
was revealed to be critical to kinetically coupling glucose metabolism to (especially the second phase 
of) insulin secretion probably via an alpha-ketoglutarate dependent hydroxylation mechanism.  
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Chapter 1 
Introduction 
1.1 Insulin secretion 
1.1.1 Diabetes mellitus 
382 million people worldwide are suffering from diabetes mellitus [1]. This degree of prevalence is 
close to what had been predicted not to happen until 2030 [2], which indicates that the incidence has 
climbed rapidly in the last decade. Due to the complications caused by long-term hyperglycemia and 
the growth of the epidemic, diabetes is predicted to become one of main killers in the near future. 
Even worse, diabetes currently can only be treated but not cured. In addition, the life-long 
management plan of this disease makes it a large economic burden for both individuals and health 
care authorities of many countries. Therefore, it is imperative to reveal the mechanisms of diabetes 
and introduce a new treatment strategy in order to meet both cost and health challenges this disease 
presents.  
Diabetes is a group of metabolic disorders characterized by hyperglycemia, where the disruption of 
carbohydrate metabolism causes excessive glucose in the circulatory system [3]. As the primary 
energy source for the human body, blood glucose levels are subject to a tight control regulated by an 
astonishingly complex mechanism, which generates a perfect balance between glucose production 
and glucose utilization. Ideally, glucose concentration should be maintained in a relatively narrow 
range (4.0 ~ 6.1 mM) despite the fluctuation caused by glucose release and glucose removal [3]. If 
plasma glucose levels are elevated, for example, after a meal, insulin will be released into the 
circulatory system in a glucose dependent manner to suppress endogenous glucose release [4] and to 
encourage glucose uptake by insulin-sensitive tissues, such as the liver, skeletal muscle and adipose 
tissue [5-7], so that the rate of glucose removal from the plasma parallels that of glucose release [8, 
9]. As the major acute glucose regulatory hormone, insulin is able to change the plasma glucose level 
in a matter of minutes and is central to maintaining glucose homeostasis. Disturbance of glucose 
homeostasis due to an insufficiency of insulin secretion or defect of insulin action, or both, will cause 
diabetes mellitus [3]. As a consequence, external insulin is absolutely required for treatment of type 1 
diabetes and may also be included in type 2 diabetes management plans.    
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1.1.2 Structures producing and secreting insulin 
Insulin is produced by beta cells in the islets of Langerhans of the pancreas. The mass of islets 
constitutes around 1~2% of the mean pancreas weight in healthy adults; the number of islets in the 
adult human pancreas ranges from several hundred thousand to several million [10]. Islets are 
aggregates of endocrine cells and contain five different endocrine cell types [11]: alpha cells, beta 
cells [12], delta cells [13], pancreatic polypeptide (PP) cells [14], and epsilon cells [15]. As the main 
population within islets of Langerhans, beta cells account for 50~80 % of the total number of 
endocrine cells in islets [11, 16-19]. The second most abundant cell type in the islets of Langerhans is 
alpha cells (15 ~ 20 %), which secrete glucagon, a hormone coordinately working with insulin and 
reciprocally regulating glycaemia [19, 20].   
With the exception of pathological conditions, beta cells can adapt to physiological demand and 
secrete the appropriate amount of insulin in the correct proportion to plasma glucose levels to 
guarantee the removal of excessive glucose from the circulatory system and to achieve the tight 
control of glucose homeostasis. For example, obese subjects or pregnant women normally release 
more insulin than individuals who are not in either of these conditions [21-23] to match the increased 
demand from glucose. Altered performance of pancreatic beta cells is linked to various types of 
disorders in diabetes. In type 1 diabetes, genetically susceptible individuals experience a significant 
loss of beta cells as a result of T-cell-mediated autoimmune reaction [24-26]. On the other hand, the 
dysfunction of pancreatic beta cells, such as loss of adaptive capacity to physiological stimuli, 
increased apoptosis, and deposition of amyloid (its precursor, islet amyloid polypeptide (IAPP), is a 
peptide co-secreted with insulin) [27, 28], contributes to the development of type 2 diabetes [10]. 
1.1.3 Mechanistic control of insulin secretion 
1.1.3.1 KATP channel dependent pathway 
Because insulin is the prime regulator of glucose homeostasis, understanding and improving 
endogenous insulin secretion is important for devising a successful diabetes management plan [29].  
Despite years of intensive research efforts from scientists dedicated to revealing the biochemical 
mechanism underlying insulin secretion, only one well-established glucose metabolism and insulin 
secretion coupling pathway has been widely accepted by the diabetes research community.  
When the extracellular concentration of glucose increases, glucose is conveyed into pancreatic beta 
cells by glucose transporter 1 (GLUT1) in humans and glucose transporter 2 (GLUT2) in rodents [30, 
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31]. An instant equilibration of glucose between extra- and intracellular space is reached rapidly [32]. 
Hence glucose metabolism in beta cells is primarily driven by substrate availability, not the transport 
of glucose across cellular membrane. It is generally believed that, instead of glucose, it is the second 
messengers generated by glucose metabolism that are required to elicit exocytosis of insulin secretory 
granules. Because of the low activity of glycogen synthesis and the pentose phosphate pathway (PPP) 
[33], most glucose fluxes into aerobic glycolysis,  a glucose metabolic process initiated and controlled 
by glucokinase [34]. The conversion of glucose to glucose-6-phosphate (G6P) by glucokinase likely 
constitutes the rate-determining step in glycolysis happening in pancreatic beta cells [35, 36]. As the 
end product of glycolysis, pyruvate establishes the tight link between glucose metabolism in cytosol 
and in mitochondria by feeding glucose-derived carbon into the tricarboxylic acid cycle (TCA cycle) 
via pyruvate dehydrogenase (PDH). Acetyl-CoA, the product of pyruvate decarboxylation, is turned 
into adenosine triphosphate (ATP) by a series of biochemical reactions in the TCA cycle and 
oxidative phosphorylation pathway (electron transport chain). Hence, the increase of extracellular 
glucose in the circulatory system eventually leads to an increase of oxidative ATP production at the 
expense of Mg-adenosine diphosphate (ADP) within pancreatic beta cells. 
ATP will bind and close ATP-sensitive K
+
 channels (KATP channels) present on the plasma membrane 
of pancreatic beta cells [37-39]. The KATP channel is a hetero-octameric complex [40, 41] composed 
of four inward-rectifier potassium ion channel (Kir6.2) subunits and four sulphonylurea receptor 
(SUR1) subunits [42, 43]. The former is the target of ATP, which can close Kir6.2 [44], while ADP 
binds to SUR1 and holds the KATP channel open. The closure of KATP channels will decrease K
+
 
conductance and cause depolarization of the cell membrane until the threshold is reached to open 
voltage-sensitive Ca
2+
-channels [45-47]. The opening of Ca
2+
-channels causes an influx of 
extracellular Ca
2+
 into beta cells along the electrochemical gradient and an increase of intracellular 
Ca
2+
 concentration, which directly triggers exocytosis of insulin secretory granules [48, 49]. Because 
ATP/ADP ratio plays a crucial role in physiological control of insulin secretion through modulating 
KATP channels, this stimulus-secretion coupling pathway is called the KATP channel-dependent 
pathway or triggering pathway [50]. 
KATP channels play a central role in maintaining glucose homeostasis, and thus is the target of current 
anti-diabetic or anti-hypoglycemia medicine aiming to either mimic or antagonize the triggering 
effects of glucose on insulin secretion [51, 52]. Sulfonylureas (e.g. tolbutamide, glipizide) are widely 
used for treatment of type 2 diabetes, because they stimulate endogenous insulin secretion by binding 
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to SUR1 and closing the KATP channel in a glucose-independent manner [53, 54]. Meglitinides 
(glinides) inhibit the KATP channel in a way similar to sulfonylureas by binding to a different site of 
SUR1 [55]. Diazoxide and other KATP channel activators, used for hypoglycemia and/or 
hyperinsulinemia, have an opposite effect of sulfonylureas by opening the KATP channel and hence 
stopping glucose and other insulin secretagogues from inducing insulin secretion [38, 51]. These 
drugs are widely used in anti-diabetic clinical treatment as well as research. 
1.1.3.2 KATP channel independent pathway 
Experiments using these KATP channel-targeted drugs provide evidence that the KATP-dependent 
pathway may not be the only avenue for nutrient-induced insulin secretion in beta cells. Even when 
KATP channels were bypassed by treating islets with a combination of high concentration of K
+
 and a 
KATP channel opener diazoxide, the glucose challenge in a physiological range can still elicit a KATP 
channel independent insulin response [56, 57]. In addition to pharmacological evidence, genetic data 
from models lacking the KATP channel is even more compelling. KATP channel knock-out islets 
unexpectedly retain glucose responsiveness and the KATP channel knock-out animals still remain 
euglycemic [58, 59]. Heterozygous knock-out (Kir6.2
+/-
 and SUR1
+/-
) mice can maintain a good 
control of glucose homeostasis and demonstrate improved ability to release insulin in response to 
elevated glucose [60, 61]. Even in homozygous knockout (Kir6.2
-/-
 and SUR1
-/-
) mice, the ability of 
islets to respond to glycemic stimuli is impaired but not abolished [62].  What supplements this 
discovery and makes it even more interesting is the effect of glucagon-like peptide 1 (GLP-1) and 
acetylcholine (Ach) on KATP channel knock-out beta cells. These two stimulatory elements 
augmenting beta cell insulin secretion in a glucose-dependent mechanism still retain their incretin 
effects on islets isolated from SUR1 knock-out mice [63, 64]. These findings together suggest the 
existence of some other second messenger(s), in addition to ATP/ADP ratio, derived from glucose 
metabolism but working independently of the KATP channel in pancreatic beta cells. This is therefore 
called the KATP channel independent pathway or amplifying pathway [64, 65]. 
1.1.3.3 Pyruvate carboxylase mediated anaplerosis 
One of the proposed mechanisms for the amplifying pathway under active investigation is pyruvate 
carboxylase (PC) mediated anaplerosis (the replenishment and increase of TCA cycle intermediates) 
for enhanced TCA cycle activity [66]. Key evidence for its involvement in the coupling of glucose 
stimulation and insulin secretion includes at least three facts. First, PC is highly expressed in 
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pancreatic beta cells [33, 67]. Second, the elevated carboxylation of pyruvate occurs in concert with 
insulin secretion [68, 69]. Third, pharmacological [69] and biological [70] inhibition of PC activity 
clearly decrease glucose stimulated insulin secretion (GSIS) in both INS-1 cells [70] and rat islets 
[71]. In agreement with all the above-mentioned data, physiologically reduced PC expression is found 
in various type 2 diabetes models [72, 73].  
1.1.3.4 Pyruvate cycling 
Because PC is highly expressed in pancreatic beta cells [33, 67], approximately 50 percent of 
cytosolic pyruvate enters the anaplerotic branch of the TCA cycle via PC as oxaloacetate (OAA) [33, 
74-77]. The physiological significance of glucose-derived anaplerosis lies not only on their role in 
TCA cycle, but also on their involvement in other pathways. Different metabolic pathways and/or 
cycles other than just TCA are formed by the efflux of TCA cycle intermediates from mitochondria to 
cytoplasm (cataplerosis, the depletion and the reduction of TCA cycle intermediates) [78] via 
different transporters, such as di- and tri-carboxylic carriers, and their conversion back to pyruvate or 
TCA cycle intermediates [79]. Some of these cycles are the pyruvate cycles, which include pyruvate-
malate cycle [80], pyruvate-citrate cycle [69, 81] and pyruvate-isocitrate cycle [49, 82],  and 
pyruvate-phosphoenolpyruvate (PEP) cycle [83]. The first three pyruvate cycling pathways have been 
proved to be quantitatively correlated with dose-dependent GSIS by 
13
C NMR analysis [76]. The 
detailed pyruvate cycling pathways are summarized in Figure 1-1. 
The biological significance of pyruvate cycling pathways might lie in the byproducts generated 
during cycling, as well as the exchange of metabolic intermediates between cytoplasmic and 
mitochondrial compartments.  The reason is simple: signals carried by mitochondrial oxidative 
metabolism need to be transported to the cytoplasm and used to activate the downstream exocytotic 
effectors acting on insulin granule exocytosis machinery. Reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) generated from all three pyruvate cycling pathways might be one of these 
cytosolic effectors [49, 81, 84]. NADPH can be produced by either pyruvate cycling pathways or the 
PPP. However,  due to its low activity, the PPP, on its own, unlikely accounts for the rise in NADPH 
content [85] occurring prior to cell membrane depolarization and Ca
2+
 elevation [86] in beta cells. 
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Figure 1-1 Pyruvate cycling pathways in pancreatic beta cells 
Glucose-derived pyruvate enters mitochondria through a pyruvate carrier in roughly equal 
proportion via oxidative and anaplerotic pathways. Approximately half of pyruvate is oxidized 
to acetyl-CoA by pyruvate dehydrogenase (PDH), and the other half is converted to oxaloacetic 
acid (OAA) by pyruvate carboxylase (PC). These two products condense to form citrate, which 
starts tricarboxylic acid cycle (TCA cycle). In addition, glucose-derived carbon is also a driving 
force for other signaling pathways, which are formed by the efficient exchange of metabolites 
between the cytoplasmic and mitochondrial matrix via a set of mitochondrial carriers, to 
generate metabolic coupling factors. These pathways are: pyruvate-citrate, pyruvate-isocitrate, 
pyruvate-malate, and pyruvate-phosphoenolpyruvate (PEP) cycles, and GABA shunt. In 
pyruvate-malate cycle, mitochondrial OAA is reduced to malate by mitochondrial malate 
dehydrogenase (MDH) and then carboxylated back to pyruvate, either by a cytoplasmic or a 
mitochondrial form of malic enzyme (ME). In pyruvate-citrate cycle, citrate is exported from 
mitochondria to cytoplasm via the citrate-isocitrate carrier (CIC), and cleaved by ATP citrate 
lyase (CL) to OAA and acetyl-CoA. The former is converted to malate by cytosolic malic 
enzyme (MEc) and then recycled back to pyruvate via a cytosolic MDH. The latter is converted 
to malonyl-CoA and then long-chain acyl-CoA (LC-CoA), which are the key components of 
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malonyl-CoA /LC-CoA hypothesis of GSIS. In pyruvate-isocitrate or isocitrate-alpha-
ketoglutarate cycle, isocitrate exits mitochondria and is then converted to alpha-ketoglutarate 
by a cytosolic NADP-dependent isocitrate dehydrogenase (ICDc). Alpha-ketoglutarate can flux 
back to mitochondria via alpha-ketoglutarate carrier (OGC). In the pyruvate-
phosphoenolpyruvate (PEP) cycle, PEP is the precursor of pyruvate and can be used to produce 
pyruvate and then OAA. OAA is converted back to PEP, which can exit mitochondria and 
translocate to cytoplasm, via a guanosine triphosphate (GTP) dependent mitochondrial 
phosphoenolpyruvate carboxykinase isoenzyme (PEPCKm). In GABA shunt, alpha-
ketoglutarate is converted to glutamate by glutamate dehydrogenase (GDH) and then used to 
generate GABA through oxidative decarboxylation catalyzed by glutamate decarboxylase. 
GABA can either leave the mitochondria for further generation of gamma-hydroxybutyrate or 
can be further metabolized to succinic semialdehyde (SSA) and then metabolized to succinate, 
which fluxes back to TCA cycle. (Adapted from [35, 87]). 
In addition to NADPH, each pyruvate cycle produces other specific products unique to stimulus-
secretion coupling, such as cytosolic acetyl-CoA and malonyl-CoA generated in the pyruvate-citrate 
cycle. It is speculated that acetyl-CoA probably exerts its effect on insulin secretion by providing the 
acetyl group needed for acetylation of many enzymes and signaling molecules, which are actively 
involved in beta cell secretion function [88, 89]. Malonyl-CoA links the TCA cycle to lipid signaling 
pathways by providing a precursor for de novo lipogenesis and altering beta oxidation via inhibition 
of carnitine palmitoyl transferase I (CPT-I) [90, 91]. Alpha-ketolutarate, which can be transported to 
cytoplasm through the pyruvate-isocitrate cycling pathway, is implicated in fuel-induced secretion 
coupling by either mediating the cross-talk between glucose and amino acid stimulated insulin 
secretion [92-94] or controlling Fe(II)-alpha-ketoglutarate dependent hydroxylase activity through 
substrate availability [95, 96].  
The fourth pyruvate cycling is pyruvate-phosphoenolpyruvate cycle [83], which might serve to 
generate guanosine triphosphate (GTP) for insulin secretion. PEP itself acts as an insulinotropic 
metabolite by suppressing okadaic acid-sensitive Ser/Thr protein phosphatase activity [97], an event 
that has been shown to augment Ca
2+
 influx in RINm5F cells [98]. 
1.1.3.5 Gamma-aminobutyric acid (GABA) shunt 
Another pathway between TCA cycle intermediates is gamma-aminobutyric acid (GABA) shunt, 
which works independently of alpha-ketoglutarate dehydrogenase to link succinate to alpha-
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ketoglutarate and produces GABA and gamma-hydroxybutyrate [99, 100]. The former serves as a 
positive feedback loop to GSIS via GABAA receptor [101, 102] and the latter helps with glucose 
suppression of glucagon secretion [103]. Like pyruvate cycling, glucose-derived anaplerosis is also 
the driving force for this pathway. 
1.1.4 Biphasic insulin secretion 
As a response to a sustained stimulation of insulin secretagogues, dynamic insulin secretion is 
characterized by the biphasic feature, a phenomenon first reported by Grodsky in rat pancreas [104-
106]  and by Cerasi  [107]  in humans in the 1960s. These observations showed that the dynamics of 
insulin secretion had a biphasic effect upon stimulation induced by an abrupt and sustained increase 
in the concentration of glucose. The first phase is relatively transient (0-10 min) and is predominantly 
characterized by a high insulin secretion peaking in the first 10 min of stimulation. This first phase is 
followed by the longer-lasting second phase initiated with lower insulin secretion rate that either 
remains stable or slowly rises as long as the glucose concentration remains high [104]. 
The characteristics of biphasic insulin secretion vary somewhat with species [108]. The insulin 
secretion of the second phase observed in rat pancreases and isolated rat islets often rise quickly and 
will eventually be well above the peak of the first phase [109-113]. However, in freshly isolated 
mouse islets or perfused mouse pancreases, the second phase has been demonstrated to be flat and 
lower than the peak of the first phase [114-117]. Consequently, the rising phase has been believed to 
be slight [118] or non-existent [114, 115, 119-121]. This difference in the magnitude of second phase 
between rat and mouse was originally attributed to a great production of cyclic adenosine 
monophosphate (cAMP) [122] and/or expression of distinct isoforms of protein kinase C [121] in rat 
beta cells. Recently, it was proved that the difference in the second phase between species was 
actually caused by the pre-culture conditions prior to the perifusion experiment, in which pre-
stimulatory glucose level can indeed plays a crucial role in either decreasing or increasing the pattern 
of second phase depending on the species being studied [123].  
Whether the biphasicity of insulin secretion is of any physiological significance or just an 
experimental phenomenon has been under debate for years. The latter position is supported mainly by 
the fact that the abrupt change of glucose concentration almost never happens in nature. Indeed, in 
real physiological conditions, plasma glucose level is elevated gradually and insulin secretion 
stimulated by oral glucose ingestion never bears any clear sign of biphasicity. However, this can be 
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easily refuted since in vivo biphasic insulin secretion elicited by hyperglycemic clamp or intravenous 
glucose administration was observed from both mouse [113] and human (six healthy volunteers aged 
16-28 with no diabetes in the family history as well four diabetic patients) [107] almost as early as in 
vitro [104-106]. Coupling data also reveal the existence of early rapid insulin response, an analogue 
of the in vitro first phase insulin secretion of beta cells, to physiological plasma glucose level. This 
early rapid insulin response can be further enhanced by gastrointestinal hormones acting as incretins 
[124]. This evidence at least demonstrates that biphasicity of insulin secretion is not an artificial 
observation due to stress from experimental conditions. The physiological significance of biphasic 
insulin secretion was revealed by further evidence showing that early insulin response serves to 
regulate postproandial glucose homeostasis in both dog [125, 126] and human [110] by acting as a 
rapid inhibitor of hepatic glucose production [127]. In contrast, the second phase insulin release was 
confirmed to exert its effects on both glucose production and utilization [127], since it takes longer 
for insulin to cross the endothelial barrier of muscle cells and activate glucose uptake and utilization 
in muscle. Moreover, data from clinical studies demonstrate that alteration of acute insulin release is 
an early sign of beta cell dysfunction in impaired glucose tolerant and type 2 diabetic patients [48, 
128-130]. Taken together, this evidence indicates that biphasic time course insulin secretion is a real 
characteristic of beta cell function rather than an artificial experimental phenomenon, and is likely 
used to dynamically optimize the insulin action on target tissues based on their different structures 
and specific functions [108]. Therefore, the study of biphasic insulin secretion mechanism will be 
helpful for both early screening and identification of pre-diabetes as well as treatment of type 2 
diabetes.  
To date, several major and non-exclusive models have been proposed to explain the mechanism of 
biphasic insulin secretion. The first model is the pool model [105, 106, 131, 132], which assumes that 
cells contain two distinct pools of insulin granules with different releasability: a small pool docked to 
the plasma membrane and ready for immediate release, the depletion of which corresponds to the 
nadir in biphasic insulin secretion, and a large pool located away from cellular membrane requiring 
translocation of insulin granule from cytosol to membrane upon stimulation [111].  However, this 
model faces some challenges, both in the timing of the first phase insulin secretion and the origin of 
released granules. Biochemical evidence observed that the first phase lasted about 10 min, while 
electrophysiological data defined it as only 100 ms [133]. Moreover, evidence generated by imaging 
techniques used to monitor exocytosis concluded that granules released during both phases of glucose 
stimulation have a similar origin, distinct from the docked pool [134, 135].  
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The second model is the signal model, which proposes that two phases of insulin secretion are 
governed by different signaling pathways. This hypothesis was mainly based on an observation that 
only fuel secretagogues are capable of inducing the second phase, and non-metabolizable stimuli can 
only elicit the first phase [133, 136-138]. This, at least, suggests that second phase insulin secretion 
depends on beta cell metabolism.  
The third hypothesis, which does not contradict either of the above-mentioned models, proposes that 
the actual insulin secretion at any moment is determined by the current glycemic challenge as well as 
previous stimulus, because glucose can elicit both an acute stimulatory effect and a time-dependent 
effect (TDE) on pancreatic beta cells [106, 107, 139-142]. TDE refers to  the observation that if the 
pancreatic beta cells are challenged repeatedly, beta cell responsiveness to subsequent stimulations 
can be either enhanced (time-dependent potentiation or TDP) [104, 106, 119, 131, 140, 143-146] or 
impaired (time-dependent inhibition or TDI) [119, 143, 144, 146]  by previous exposure to stimuli. 
The type and magnitude of the subsequent insulin responses depend on the type of secretagogues, as 
well as condition of exposure, including secretagogues’ concentration (dose dependency) and 
duration (time dimension) of stimulation applied: high concentrations and long durations generate 
amplification of subsequent insulin responses, while low concentrations and short pulses of 
stimulation tend to induce a refractory state[104-107, 119, 131, 139-145]. Hence, the biphasic insulin 
release might reflect the net balance between TDP and TDI on the acute stimulation [147]. One 
important piece of supportive evidence is that a tight correlation was discovered between the 
magnitude of TDP and the slope of second-phase insulin response [144]. In this model, biphasic 
insulin release is a function of the combined regulation of acute GSIS by both TDP and TDI events 
initiated by glucose, each of them having its own kinetics and dose dependence. 
Based on current available literature, it is very hard to conclude which model accurately describes the 
actual mechanism underlying the biphasic insulin secretion.  
1.1.5 Concluding remarks 
Compared to all above-mentioned intensive research efforts being applied to diabetes during the last 
several decades, our knowledge about the true biochemical mechanism underlying nutrient-induced 
insulin secretion remains limited. Although a large amount of data has been collected, many new 
questions have been simultaneously created. It is not at all unusual to see contradictory results coming 
from similar studies with different approaches. A good example is the study examining whether the 
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PPP [33, 148-150] or malic enzyme (ME) [49, 151-159] is involved in regulation of GSIS. Data as 
well as conclusions from different studies clearly oppose each other.  
Admittedly, in some cases the problems are caused by differences between the experimental 
conditions used in different studies. For example, the species difference of second phase insulin 
secretion was proved to result from pre-culture conditions as well as pre-stimulatory glucose levels 
[123]. Disagreement about the exact role of malonyl-CoA decarboxylase in GSIS is due to the 
presence or absence of exogenous free fatty acid (FFA) in the stimulation buffer [160, 161].  
More importantly, it is an inherent feature of the traditional research strategy, in which observation is 
normally focused on the change of one or several effectors caused by manipulation (decrease or 
increase) of up-stream factor(s). However, it is almost never this case in nature. In fact, most 
signaling molecules, including both metabolic factors and proteins, lie at the crossroads of several 
metabolic (or signal transduction) pathways and are involved in multiple biological processes. So, any 
manipulation of even one up-stream signaling molecule will most likely cause significant changes in 
the activity of several downstream metabolic pathways, including hundreds of metabolites through 
signal transduction cascades. Missing some parts of the whole signal transduction network is 
common, because classical biochemical approaches only allow the determination of one molecule at a 
time and hence are prone to cause misinterpretation of observations under investigation. The best 
example is ATP. No manipulation of ATP will alter the activity of the KATP channel dependent 
pathway without affecting countless other metabolic and signal pathways. 
Therefore, a different and powerful approach is needed for detection of global biochemical events to 
overcome this intrinsic drawback in traditional research strategies. This requires that relevant research 
should aim at studying and understanding the metabolic network as whole and this should be done at 
the metabolome level.  
1.2 Metabolomics 
1.2.1 Introduction of metabolomics 
Generally speaking, metabolomics refers to the systematic determination of either a few metabolites, 
or the profile of the whole metabolome, the total set of all native metabolites presented in and 
required for maintaining the normal function of a particular biological system [162], e.g. cell, tissue, 
organ or organism [163].  
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Metabolites are low molecular weight molecules produced by metabolism, which is composed of a 
series of life-sustaining enzymatic chemical reactions supplying the carbon and energy resources 
needed for cells. Enzymes coordinately organized to serve a certain function within a living system 
are called metabolic pathways. Unlike genes, mRNA transcripts, or proteins, which have different 
variants,  isoforms or even post-translational modifications, metabolites (especially those produced by 
primary metabolism) preserve similar or even exactly the same chemical structure irrespective of their 
location or species and are usually well-connected to other metabolites to form a whole metabolic 
network. It is very difficult to estimate the exact number of endogenous metabolites in different 
species. The present number of metabolites in humans is predicted to be 40,000 by the Human 
Metabolome Database (HMDB) [164], which is much less than what has been reported for genes or 
proteins. Although the plant and fungal kingdom is predicted to have 200,000 and 400,000 
metabolites, approximately 5000 of them might be actually present in the well-studied plant model 
Arabidopsis Thaliana [165]. This is definitely an advantage of metabolomics over other functional 
genomics studies. These two features, especially conserved chemical structures spanning the species 
barrier, strongly indicate that metabolites are central to maintaining cells viability and function. 
Since they are the end products of a cellular process in living systems, metabolites can directly link 
phenotype to their underlying genetic source and the dynamic changes of metabolites reflect the 
integrative activity resulting from all previous levels of regulation and control mechanisms in an 
entire biochemical cascade. Actually, an interference of a biological system at any level (genes, 
mRNA, proteins) will be amplified, accumulated and eventually manifested by either quantitative or 
chemical change of metabolites both spatially and temporally. In other words, the metabolome is the 
net function of an integrated system formed by multiple levels of cellular process, including genome, 
transcriptome, and proteome, and is further influenced by environmental stimuli, healthy behavior 
and pharmaceutical interventions. Hence, metabolomics is different and complementary to other 
functional genomics studies and can provide a unique advantage for mechanistic studies. To date, 
metabolomics has been widely used in studying environment stress [166], toxicology [167], 
pathophysiology [168, 169], pharmaceutics [170], nutrition [171-174], and phenotypic 
characterization as well as clinical diagnosis [175-177]. 
1.2.2 Target and untargeted metabolomics 
Depending on the objective of studies, metabolomics can be divided into two major groups: targeted 
and untargeted [163, 178] metabolomics.  
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Targeted metabolomics, which requires the known chemical structures of metabolites and the 
establishment of a standard curve built upon proper internal and/or external standards analysis, is a 
selective identification and an absolute quantification of a few number of pre-defined compounds 
precisely from crude extract [163]. The major disadvantage of this approach is that it is not helpful for 
the discovery of biomarkers or the survey of problems with unknown mechanisms.  
Different from targeted metabolomics, untargeted metabolomics focuses on a comprehensive 
determination of the whole metabolome and comparison of relative abundance of various metabolites 
in different experimental conditions. The aim is to discover biomarkers, some metabolites used to 
indicate a certain biological function. Because of this particular purpose, untargeted metabolomics 
poses both theoretical and practical challenges on unbiased analysis at each level ranging from 
sample preparation, data acquisition to data analysis and data mining.  
  
Figure 1-2 Schematic summary of MS-based targeted and untargeted metabolomics 
(A). Targeted metabolomics. Stable isotope-labeled standards are added to the sample prior to 
sample extraction and derivatization. The MS signal intensity of stable isotope-labeled 
standards is then used to establish a standard curve for absolute quantification of metabolites 
concentration determined by analytical instrument.  (B). Untargeted metabolomics. Samples 
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with different replicates are collected from two different conditions (perturbed vs. 
unperturbed) designed to characterize a certain function, then processed and analyzed by 
analytical instruments, which will generate two independent data sets. These data sets will be 
searched against currently available spectral libraries for metabolites identification. In the 
meantime, a global comparison of two data sets by multivariate statistical analysis can identify 
significant biomarkers responsible for the differentiation of these two different experimental 
conditions. However, the absolute concentration of analytes is unknown. (Adapted from [169]) 
1.2.3 Metabolite extraction 
As the product of enzyme-catalyzed reactions, metabolites are constantly produced, consumed, 
degraded, and excreted by cells and their half-lives are at the scale of seconds or even milliseconds 
[179-181]. Therefore, the rapid turnover of metabolites resulting from the high activity of metabolic 
enzymes defines the necessity of the immediate inactivation of metabolic enzyme activities, which is 
the first and utmost step in metabolites extraction to avoid further biochemical conversions or 
chemical degradation. An effective quenching of the metabolic enzymes is normally achieved through 
rapid changes in temperature (< -40 ºC or > 80 ºC) or pH (pH < 2.0 or pH > 10). Normally, perchloric 
acid, trichloroacetic acid (TCA), potassium hydroxide (KOH), and sodium hydroxide (NaOH)  are 
used for the creation of an extreme pH environment [182-186], but this method generally requires pH 
neutralization in the next few steps and is limited when extracting pH-sensitive metabolites. Liquid 
nitrogen or ethanol/dry ice bath inactivates cellular metabolism by generating an extremely low 
temperature. Other cold organic solvent-based solutions, e.g. methanol, ethanol, are also effective in 
quenching metabolism by destabilizing enzymes [165].  
The second step usually includes the disruption of the cell membrane and separation of metabolites 
from the complex biological matrix. Many different methods can be used to disturb the cell 
membrane and to release intracellular metabolites. Mechanical-based cell disruption, including 
ultrasonics [187-190], microwave [191], or even manual grinding, breaks the cell envelopes down 
mainly through the mechanical force applied to cells. Non-mechanical disruption methods release 
intracellular contents from cells by using traditional enzymatic (e.g. glycosidases, lysozyme [192, 
193]), chemical (e.g. organic, acidic, alkaline solvent) or physical (freeze-thawing cycle, or heating) 
agents to increase permeability of cells. Non-mechanical disruption methods normally have 
restrictions on temperature, pH or specificity. For example, heating most likely will cause loss of 
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temperature-sensitive metabolites. Lytic enzymes generally require an aqueous medium and mild 
temperature, which is incompatible with conditions used for inactivation of metabolism.  
Unlike other functional genomics, which contain structurally conserved molecules (four nucleotides 
for genomics and transcriptomics, twenty one amino acids for proteomics), metabolomics aims at 
analyzing a group of molecules with various chemical properties and structures ranging from ionic 
inorganic species to hydrophilic carbohydrates, hydrophobic lipids, acidic carboxylic acids, polar and 
non-polar amino acids as well as vitamins. Therefore, although the number of metabolites is much 
less than that of proteins or genes, the chemical complexity makes it virtually impossible to establish 
a simple and absolutely unbiased extraction method for a whole metabolome. Up to date, almost no 
such comprehensive extraction techniques have been published showing acceptable reproducibility, 
robustness, and recovery for all classes of metabolites [194, 195]. One general practice is to adapt a 
sampling method for as many classes of metabolites as possible by incorporating a multi-step 
purification procedure needed for isolation of metabolites with different polarity and molecular 
weight to gain a broader perspective of the metabolome. However, it will be a time-consuming, 
laborious process and can easily add artifacts to extracted metabolite pools. An alternative and widely 
used approach is to sacrifice several classes of compounds for a good and stable yield of other types 
of metabolic intermediates favored by the extraction method, in which comprehensiveness is traded 
off for reproducibility. For example, a method based on a nonpolar organic solvent, which is 
incompatible with water soluble and polar metabolites, can be safely used for selective extraction of 
insoluble or nonpolar metabolites. Practically, a multiple solvent mixture is generally used for the 
purpose of increased coverage of different classes of metabolites. For example, cold 
methanol/chloroform/water mixture, stepwise [196] or mixed simultaneously, was successfully 
applied to the extraction of both polar- and non-polar metabolites [194, 195, 197-201]. However, it 
was proven to be not efficient for nucleotides even when chloroform’s toxic and carcinogenic effects 
are not taken into consideration. Cold methanol and water mixture (< 20 ºC) is a simple and efficient 
method for extraction of polar and mid-polar metabolites from animal cells [182, 186, 194, 202-204].  
The concentration of steady-state metabolites may range widely from 10
-1
 to 10
-7
 M [205, 206]. In 
addition to sampling of a wide range of compound classes, the extraction process must also preserve 
the concentrations of metabolites. It is important that these intracellular metabolites are released in a 
quantitative manner and the ratio of metabolites concentration in their original state remains 
unaffected. Otherwise, the extraction process will add even more complexity to metabolomics 
analysis. The wide range of chemical properties and concentrations of intracellular metabolites as 
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well as the dynamic regulation by enzymes involved in metabolic pathways makes the sample 
preparation process for untargeted metabolomics a very challenging task.  
1.2.4 Instruments used for metabolomics 
The significant improvements in modern analytical chemistry instrumentation over the last several 
decades have made the study of metabolomics much more accessible. A wide range of analytical 
platforms, such as ultraviolet–visible spectroscopy [207], fourier transform infrared spectroscopy 
(FT-IR) [208-210] or raman spectroscopies, mass spectrometry (MS) [163, 211, 212], and nuclear 
magnetic resonance (NMR) [213-217], have been applied to analyze metabolites. Because each 
technology is unique and provides different information, the research objective and the sample under 
analysis should be considered when choosing an instrument to work with. 
Generally speaking, MS is the most widely used analytical technique for metabolomics research 
because it is superior to other instruments in terms of simplicity and sensitivity. So, MS is widely 
used for identification of low-abundant metabolites. Newly developed mass spectrometers with 
improved sensitivity and/or resolution can even capture samples with concentration at fmol level and 
can support identification of metabolites without the need to search a MS spectral library. Even 
though MS spectra only display masses of the ionized molecule and its fragments, the abundance of 
structural information contained in MS spectra is much more than what has been interpreted and 
utilized.  
The matrix effect from crude extract is a notorious part of analytical technique so an efficient 
chromatographic (gas- or liquid-) or electrophoretic separation prior to MS is necessary for 
metabolomics analysis. The coupling of metabolites analytical technology to chromatographic or 
electrophoretic separation, e.g. gas chromatography (GC) [203, 212], liquid chromatography (LC) or 
capillary electrophoresis (CE),  can remarkably expand the capacity of MS-based metabolomics 
technologies by enhancing their resolution, sensitivity and selectivity, because the well-known co-
elution and ion suppression effects due to complex biological background are minimized [218, 219]. 
For the last thirty five years, GC coupled with MS has been commonly used in the field of 
metabolomics [220-222] and can detect different metabolites with various chemical properties, as 
long as they were volatile. Metabolites with low thermal stability, high polarity and low volatility are 
hard to measure and need to be derivatized and converted to GC-measurable molecules [223, 224]. 
Although its application is limited by molecular weight, thermal stability, polarity and volatility of 
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metabolites, GC-MS is still one of the most popular technologies for metabolomics studies due to the 
superior separation power of GC column, the well-developed deconvolution algorithms [225, 226] as 
well as the comprehensive and searchable MS spectral databases [223] generated from globally 
standardized operations in GC-MS labs. Additionally, GC-MS data has some well-described 
algorithms for automated raw data processing. AMDIS (automated mass spectral deconvolution and 
identification system) offers a variety of enhanced functions, such as noise reduction, spectra 
deconvolution, peak detection, and compound identification, while LC-MS or CE-MS lacks the 
equivalence of the same competency. Moreover, GC-MS has some well-established, comprehensive 
libraries to aid users with metabolite identification, while LC-MS and CE-MS require additional 
implementation of vendor independent and metabolites specific libraries. Examples of such libraries 
include NIST11/2011/EPA/NIH Mass Spectral Library containing 243,893 EI spectra, and 10
th
 
edition of Wiley Registry of Mass Spectral Data containing 719,000 spectra. These are two 
commercially available libraries for small chemical molecules, natural products as well as drugs. 
FiehnLib is a library containing both retention index and mass spectra from quadrupole and time-of-
flight only for metabolites below 550 Da [227].  
On the contrary, LC-MS offers its own set of unique advantages, because it is capable of covering 
different classes of metabolites with a broad range of polarity, molecular weight and chemical 
structure [228-230]. Reverse-phase liquid chromatography (RPLC) has been a well-established 
method for separation of metabolites prior to MS detection without requirement of any pre-treatment 
of metabolites samples. Recently, a newly developed method called hydrophilic interaction liquid 
chromatography (HILIC) was shown to be more friendly and efficient for separation of ionic or 
highly polar metabolites [231]. Ultra-performance liquid chromatography (UPLC) [232] displays 
better resolution, retention time reproducibility, and signal-to-noise ratio than HPLC [229, 230, 233-
235]. Following current trends, substantial improvement of metabolomics data acquisition techniques 
can be predicted to happen in the near future especially for liquid chromatography based methods.  
An even more promising separation technique is CE-MS. CE-MS  separates analytes in submillimeter 
capillaries according to their ionic mobility under the influence of an electric field and hence allows 
both charged and uncharged metabolites to be separated in one single run so that multiple metabolites 
classes can be potentially analyzed simultaneously [236-241]. CE-MS is therefore especially 
attractive for researchers doing high-throughput untargeted metabolomics study. Other advantages of 
CE, such as low sample volume and relatively short analysis time, give CE the upper hand over GC 
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and LC, and also contribute to its bright future of CE serving as the major analytical technique for 
metabolomics. 
NMR is another widely used analytical technique in the field of metabolomics. NMR is particularly 
useful for characterization of structurally unknown compounds and also has the ability to distinguish 
between isomers [242], e.g. citrate vs. isocitrate. Additionally, NMR-based metabolomics is 
characterized by its non-destructive data collection and minimum sample preparation process so that 
samples in different conditions can be saved for further analysis [243]. NMR is also well-known for 
being highly quantitative, reproducible and non-selective [213] and hence can be promisingly applied 
to unbiased measurement of all classes of metabolites and even metabolic fluxes [244, 245]. 
However, its inherently low sensitivity (compared to MS) resulting from natural abundance of 
chemical atoms prevents it from being as popular as MS in detecting low-abundant metabolites at the 
current stage. The sensitivity of NMR can be improved by the extension of analysis time, application 
of high magnetic fields and the proper use of cryogenic probes. For example, 
13
C NMR spectroscopy 
can only detect samples in μmol to mmol concentration range, or nmol at high fields with new 
cryoprobes [246].  Due to the low sensitivity of NMR and the prevalence of 
1
H, most NMR-based 
metabolomics data has been generated by 
1
H NMR spectroscopic investigations of biofluids, such as 
urine and plasma. The application of robotic flow injection methods further enables the high-
throughput analysis of biofluids samples--as many as 100 samples per day [247]. NMR can also be 
expanded to analyze the intact tissue samples by using a technique known as 
1
H MAS NMR 
spectroscopy [248-250]. 
Overall, MS and NMR are two major analytical techniques used in metabolomics. They have their 
own pros and cons and the combination of these two complementary spectroscopies will be helpful to 
generate comprehensive and integrated metabolomics data. 
1.2.5 Data analysis and data mining 
Data analysis of targeted metabolomics simply quantifies predefined metabolites by using the 
information provided by internal or external standards, which is a traditional and mature analytical 
technique. However, untargeted metabolomic data is rich in information, and data analysis must 
follow a different approach.  
The first goal of untargeted metabolomics data analysis is to define the unknown compounds based 
on their chemical structures (size, molecular weight, retention time, element composition, isotope 
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ratio, mass spectral fragmentation patterns), which are revealed by structure analysis. For this 
purpose, one strategy is searching spectra against (metabolite-specific) spectral libraries, such as The 
Human Metabolome Database (HMDB) [164, 251, 252], Golm Metabolome Database (GMD) [253], 
METLIN [254-256], Fiehn [227], and National Institute of Standards and Technology 
(http://www.nist.gov/). A well-organized and information-rich database normally allows the 
automatic and high-throughput metabolite identification based on their unique physical and chemical 
properties revealed by raw data collected from analytical techniques. Such chemical identification 
converting raw spectroscopic data to corresponding metabolites is the utmost important step in a 
successful metabolomics study. Unfortunately, compared to the well-developed genes and proteins 
databases, these libraries need further improvement. Currently, there are still no public spectral 
libraries specifically devoted to endogenous metabolites. An equivalent strategy for metabolites 
identification without the requirement of databases is fourier transform ion cyclotron resonance (FT-
ICR) MS, which has a high enough resolution to directly generate the empirical formulae of 
metabolites. 
The second objective of data analysis for untargeted metabolomics is the quantitative comparison of 
metabolite levels between parallel experimental conditions with a goal to link the relative change of 
metabolites abundance to the functional assignment which is supposed to be unraveled by an 
appropriate design of comparative experiments. Due to the inherent complexity of metabolomic data 
sets, classical statistical tools, e.g. student’s t-test, cannot fulfill this task and hence a special data 
handling and analysis tool, multivariate analysis (MVA), is needed to handle and understand the 
multidimensional metabolomics data set.   
The goal of MVA is to provide an easily interpretable data set for ongoing research with a proper 
mathematical approach to facilitate the correct identification of metabolites responsible for the 
classification of samples. For this purpose, MVA simplifies the complex metabolic data table by 
reducing the dimensionality of original complex data sets to much fewer variables with minimal loss 
of information contained in original data matrix. The advantage of MVA versus traditional statistics 
methods lies in the fact that MVA can identify the underlying data structure between observations, 
variables, and between both observations and variables that might be obscured in raw data sets. MVA 
can also compare the relative importance between all predicted factors since the metabolomics data 
set, including the whole metabolic network rather than one or several metabolic pathways, is analyzed 
as a whole.  
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Two major MVA classes can be used for metabolomics data analysis, unsupervised and supervised. 
Unsupervised MVA, such as hierarchical clustering analysis [257-260], principal component analysis 
(PCA) [261], self-organizing maps [257, 262], and independent component analysis [263], is a 
powerful analysis tool when nothing is known about the class information of samples and hence this 
is normally used for an overview of metabolomics data profiles. For example, it can be used to 
identify the grouping, trends, and outliers of a data set. In contrast, supervised MVA only deals with 
the data set when the information regarding classes is already clear and can reveal the quantitative 
relationship between observations and variables, which are grouped into two different data tables (X 
and Y). X normally contains spectral data and Y is commonly reserved for experiment conditions, 
like treatment of samples, duration of treatment, study objectives, etc. Hence, supervised MVA is 
commonly used as the typical data handling tool for correct identification of biomarkers. Many 
algorithms are used for supervised MVA [264], such as discriminant analysis [265], partial least 
squares (projection to latent structures) (PLS) [266-269], ANNs [270], rule induction [271, 272], 
inductive logic programming [273], and evolutionary computation [274, 275]. If a data table contains 
qualitative value, such as treatment information of samples, partial least squares discriminant analysis 
(PLS-DA) [266, 276-280] can be used to replace PLS. But system variations in the X matrix that are 
unrelated to the Y matrix will negatively affect PLS models, the interpretation of data as well as the 
identification of biomarkers. To overcome this inherent limitation, orthogonal projection to latent 
structures (OPLS) [281, 282] is created as a modification of PLS. OPLS is able to separate system 
variations into two parts: Y-relative (predictive) and Y-irrelative (orthogonal) . So, the interpretation 
of data will not be affected by Y-orthogonal variations since only the variations relevant to Y matrix 
are used for modeling. Analogously, PLS-DA also has its equivalence, called OPLS-DA [283]. 
Another advantage of OPLS is it is a cross-validated method, which provides more reliable modeling 
than simple correlation analysis of variables against class [284].  
Projection-based MVA, e.g. PCA, PLS and OPLS, assumes that existence of latent variables [285], 
which are not necessarily measurable as observable variables (metabolites). Latent variables can 
represent the aggregation of many relevant observable variables so that they help to reduce the 
dimensionality of data sets. Latent variables are weighted. That means the most important latent 
variable, which is called the first principal component in PCA or the first predictive/orthogonal 
component in PLS and OPLS, describes the largest variations of the original metabolite data matrix. 
The second latent variable has the second largest discriminating power and so on [286]. The plot of 
observations (samples) along the first few latent variables provides a visualized summary of all 
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samples in the original metabolic data table, which is called score plot. Score plot can not only find 
clusters, but also reveal the strong outliers, which is the observation outside the Hotelling’s T2 ellipse 
(95% confidence interval) plot [287]. The closer the data points representing samples are in score 
plot, the more similar they are to each other. DModX (distance to model) can also be used to detect 
the outliers based on the distance of observations to the model plane [288, 289]. Likewise, a loading 
plot is able to show the relationship between all variables in a way similar to the score plot. Normally, 
all variables are equally important regardless of their actual concentration for MVA analysis, because 
they are first centered by subtracting the mean value, dividing their standard deviation and then unit 
variance (UV) scaled. This scaling is good to rescue the false negative results due to the low intensity 
of metabolites. These plots are basic but powerful tools to qualitatively understand metabolomics 
data. 
One risk with MVA is data overfitting. Hence, validation is necessary to avoid issues such as the bias 
against certain variables, or a high false discovery-rate. A common validation method requires two 
data sets: one is training and another is predictive. The former will generate a R
2
, which indicates the 
goodness of fit and the latter will have a Q
2
 parameter, which reflects the goodness of prediction. The 
high value of both parameters indicates a good fit, but a high R
2
 with decreasing Q
2
 generally 
suggests a problem of overfitting. 
In order to do MVA, data need to be arranged into a proper table, where each row is a sample (it is 
referred to as “observation” in MVA) and each column represents a metabolite or a putative 
metabolite (called “variable” in MVA) measured by spectroscopies. Due to the two dimensional 
nature of hyphenated instruments (e.g. GC-MS, UPLC-NMR), generation of such a data table 
requires the pre-processing of raw data by proper deconvolution algorithms [225, 258, 290-293], such 
as AMDIS [225, 291], LECO ChromaTOF (Leco Corporation, St. Joseph, MI) [294], AnalyzerPro 
(SpectralWorks, Runcorn, United Kingdom). On top of that, appropriate peak alignment methods 
[295, 296] are needed to overcome the variability of chemical shift or retention time, such as MZmine 
[297, 298], MetAlign [299, 300], MathDAMP [301], XCMS [302, 303], metaXCMS [304, 305], 
XCMS online [306, 307], and SpectConnect [308]. 
Overall, as an integrated part of untargeted metabolomics, MVA is a powerful and robust 
chemometric tool for data analysis. 
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1.2.6 Future outlook 
Metabolomics is a relatively new discipline and is rapidly expanding. Its further progress needs the 
support from improved analytical instruments, bioinformatics as well as the establishment of data 
regulation standards within this community. To meet the growing challenge of metabolomics 
research, multidimensional chromatography [309-313] has been tested aiming at improving the 
sensitivity, resolution, comprehensiveness, and throughput of this method. Similarly, efforts to 
improve the NMR spectroscopy sensitivity will be likewise continued. Like other functional 
genomics, metabolomics will ultimately require the development of agreed standards of data 
generation, analysis, management, publication, and sharing within the community, which was 
recently initiated by NIH in 2005 [314-317], but still needs further support.  
1.3 Hypothesis 
Metabolic pathways play an imperative role in coupling glucose metabolism to insulin secretion. 
However, the complete understanding of the mechanism underlying GSIS remain unresolved. We 
hypothesize that, in addition to ATP, glucose metabolism must generate other metabolic coupling 
factors to control pancreatic beta cell secretion function. In this dissertation, a GC-MS based 
untargeted metabolomics approach will be established and be used to investigate different aspects of 
GSIS and to reveal the underlying mechanisms. 
1.4 Overall objectives 
The purpose of my thesis is to establish a GC-MS based untargeted metabolomics approach to reveal 
the unknown mechanisms in regulation of GSIS. It will be comprised of four parts: 
1.4.1 Aim 1 
To establish a feasible untargeted metabolomics platform from sample preparation to data analysis.  
Our GC-MS based untargeted metabolomics will be applied to study the mechanism underlying GSIS 
and any discovery will be verified in both INS-1 832/13 cell line and islets of Langerhans models.  
1.4.2 Aim 2 
Glucose induces biphasic insulin secretion in islets beta cells. To study the kinetic aspects of GSIS, a 
time-resolved metabolome analysis was performed to investigate the mechanism controlling the 
second phase of insulin secretion in INS-1 832/13 cells.  
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1.4.3 Aim 3 
Pancreatic beta cells have a memory, which is called time-dependent effects (TDEs), of previous 
applied insulin secretagogues. So, their secretion activity is determined by the stimuli that cells are 
currently exposed and previously challenged. In this part, a TDEs model was created on INS-1 832/13 
cells and was studied by using a metabolomics approach.  
1.4.4 Aim 4 
Alpha-ketoglutarate was proved to be an important metabolic factor coupling glucose metabolism to 
insulin secretion. A metabolomics approach was used to discover the downstream effectors of alpha-
ketoglutarate and study alpha-ketoglutarate-mediated hydroxylation in regulation of insulin secretion 
and its underlying mechanisms. 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
The clonal beta cell line 832/13, derived from the parental INS-1 rat insulinoma cells, was kindly 
provided by Christopher Newgard [318]. INS-1 832/13 cells were cultured at 37°C and 5% CO2 in 
RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 10 mmol/l HEPES, 2 mmol/l L-glutamine, 1 mmol/l sodium pyruvate, and 50 μmol/l 
beta-mercaptoethanol. 
2.1.2 Animals 
Islets were isolated from Sprague-Dawley rats. All animal experiments were approved by local 
Animal Care Committees at the University of Waterloo and handled according to the guidelines of the 
Canadian Council on Animal Care.  
2.1.3 RT-PCR primers 
Primer sequences for target genes are:  
Prolyl hydroxylase 1 (PHD1): 
PHD1 forward (AGC AAC AGC ACT ACC CAT AGC AGT),   
PHD1 reverse (AGG CAC AAT ATA GTC CAA GGC CAG),  
Prolyl hydroxylase 2 (PHD2): 
PHD2 forward (AAG ATC ACC TGG ATC GAG GGC AAA),  
PHD2 reverse (CATG GCT TTC GTT CGG CCG TTT AT),  
Prolyl hydroxylase 3 (PHD3): 
PHD3 forward (ATGA AGT TCA GCC CTC CTA TGC CA)  
PHD3 reverse (TCA CAC CAC CGT CAG TCT TTA GCA),  
Hypoxia-inducible factor 1-alpha inhibitor (FIH-1)  
FIH-1 forward (TGC AGC AAA CAC TCA ATG ACA CCG),  
FIH-1 reverse (TCA CAT TCC CTT CCA TGC CGA TGA). 
Aryl hydrocarbon receptor nuclear translocator (ARNT)  
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ARNT forward (GCG GCG ACG GAA CAA GAT GAC A) 
ARNT reverse (ACA CCA CTC GGC CAG TCT CAC A) 
Glucose transporter 2 (Glut2)  
Glut2 forward (CCT GGC CGG GAT GAT TGG CA) 
Glut2 reverse (AGG CCC GAG GAA GTC CGC AA) 
Glucokinase (GK)  
GK forward (ATG CTG GAT GAC AGA GCC AGG AT) 
GK reverse (TCG GGG ATG GAG TAC ATC TGG TG) 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)  
GAPDH forward (GGC TCT CTG CTC CTC CCT GTT) 
GAPDH reverse (GTG AGA CCC AGA CTT CTC CAT G) 
Pyruvate kinase muscle isozyme 1 (PKM1)  
PKM1 forward (TGG AGG CCA GCG ATG GAA TCA) 
PKM1 reverse (GCT CTT CAA ACA GCA GGC GGT) 
pyruvate kinase muscle isozyme (PKM2) 
PKM2 forward (TGG AGG CCA GCG ATG GAA TCA) 
PKM2 reverse (GCG GCG GAG TTC CTC GAA TAA) 
PPIE peptidylprolyl isomerase E (cyclophilin E)  
Cyclophilin E forward (AGA TGG CAC AGG AGG AAA GAG CAT) 
Cyclophilin E reverse (AGG GTT TCT CCA CTT CGA TCT TGC) 
2.1.4 siRNA duplex construction and transfection 
Two siRNA duplexes were constructed against each target gene. Relative to the start codon, the 5’ 
end of the siRNA target sequence corresponded to the following nucleotide in: 
Prolyl hydroxylase 1 (PHD1/EGLN2, GenBankTM accession number NM_053046.3):  
siPHD1-1, nucleotide 506 (CAA GUU CUA GGC UGA GGG AGG AAG C),  
siPHD1-2, nucleotide 292 (GCG UUG GUU ACC AAG GAG UGC CAG C).  
Prolyl hydroxylase 2 (PHD2/EGLN1, GenBankTM accession number: NM_022051.2):    
siPHD2-1, nucleotide 513 (CCC UCA UGA AGU ACA GCC UGC AUA C),  
siPHD2-2, nucleotide 112 (CAA CUG GUC AGC CAG AAG AGU GAC T).  
Prolyl hydroxylase 3 (PHD3/EGLN3, GenBankTM accession number: NM_019371.1):   
siPHD3-1, nucleotide 914 (CCA GGA AAU GGA ACA GGU UAU GUT C),  
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siPHD3-2, nucleotide 1716 (GGA CGA UUA CGG ACA ACC UGA UGA C).  
A previously described siRNA sequence (5’-GAGACCCUAUCCGUGAUUA-3’) with no known 
gene homology was used as a control (siControl) [81, 84, 319]. 
2.1.5 Reagents 
All reagents were purchased from SIGMA unless otherwise specified. Anti-HIF1alpha antibody was 
purchased from Santa Cruz. Pierce™ ECL Western Blotting Substrate (32106) was purchased from 
Thermo Scientific. 
2.2 Methods 
2.2.1 Insulin secretion assay 
Insulin secretion and protein content assays were performed as previously described [318, 320, 321]. 
Briefly, cells (or islets) were incubated twice in experimental media containing low glucose 
concentration for 1 hour (0.5 hr for islets) and then incubated for 2 hours at the indicated glucose 
concentration unless otherwise specified. The experimental medium was a Krebs-Ringer-bicarbonate-
Hepes (KRB) solution consisting of 118 mM NaCl, 5.4 mM KCl, 2.4 mM CaCl2, 1.2 mM KH2PO4, 
5mM NaHCO3, 10mM HEPES, 1.2 mM MgSO4 and 0.2% BSA at pH 7.4. The supernatant was taken 
and insulin was measured by RIA using the Coat-a-Count kit (SIEMENS, Los Angeles, CA). 
2.2.2 Pancreatic islet isolation 
Islets were harvested from adult male Sprague-Dawley rats weighing 250–300 g and cultured as 
described previously [322-324]. Briefly, animals were anesthetized with 60 mg/kg sodium 
pentobarbital. Islets were isolated by collagenase (SIGMA) digestion and cultured in RPMI 1640 
growth medium supplemented with 10% fetal bovine serum, 10 mM HEPES (Sigma), 1% antibiotic-
antimycotic solution (Hyclone), and 11 mM glucose. 
2.2.3 Cell viability assay 
Cells were cultured for the desired test exposure period. At the end of experiment, the exposure buffer 
was replaced with 500 µL/well of RPMI 1640 and CellTiter-Blue® (Promega G8080) reagent 
mixture. Cells were incubated in the mixture at a standard cell culture condition for 2 hours. At the 
end of incubation, the plate was shaken for 10 seconds and 100 µL of RPMI and the CellTiter-Blue® 
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reagent mixture was transferred to 96-well plate for the measurement of ﬂuorescence at 560 and 590 
nm. 
2.2.4 Glucose utilization assay 
Cells were cultured with the radiotracer [5-
3
H] glucose at 0.08 Ci/mol, and samples were processed 
for measurement of glucose utilization as previously described [325]. Briefly, cells were incubated 
with [5-
3
H] glucose containing KRB solution for the specified time and then the supernatant 
containing [5-
3
H] water was mixed with 10% perchloric acid. The mixture was equilibrated with 0.5 
ml of water sealed in scintillation vial at 50 ºC for 18-24 h. Following this vapor-phase equilibration 
step, sample tubes were removed from the vial cooled to room temperature, and mixed with 
scintillation mixture (Bio-Safe, Research Products International).  
3
H2O content was determined by 
counting over a 5-min period on a PerkinElmer liquid scintillation spectrometer and used as indicator 
of glucose utilization.  
2.2.5 In situ mitochondrial bioenergetics 
INS-1 832/13 cells (2×10
4
 cells/well) were plated on a Seahorse Bioscience XF24 cell culture 
microplates and kept at 37°C cell culture incubator until confluent. Similarly, islets (50 islets/well) 
were seeded onto Seahorse Bioscience XF24 islets culture microplates and kept at 37°C incubator the 
day before experiment. A disposable sensor cartridge, embedded with 24 pairs of fluorescent 
biosensors (oxygen and pH), in Seahorse Bioscience XF assay kit was pre-calibrated the day before 
experiment. On the experiment day, cells at 100% confluence were incubated with KRB buffer 
containing low concentration glucose for 2×60 min at 37℃ before loading into a Seahorse Bioscience 
XF24 respiratory machine. Cells were then treated sequentially with low glucose (2 mM glucose), 
high glucose (16.7 mM final concentration), oligomycin (5 µM), 2,4-dinitrophenol (50 µM) and 
pyruvate (25 mM), and rotenone (5 µM) and myxothiazol (5 µM). Oxygen consumption within a 
transient micro chamber in each of the 24 wells created by the sensor cartridge was determined by a 
XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA)  as previously described 
[326, 327] to test the oxygen consumption rate of cells at rest level, glucose-stimulated oxygen 
consumption, maximum respiratory capacity, and proton leak-dependent respectively as Figure 2-1 
shows. Mitochondrial respiration was calculated by subtracting extra-mitochondrial respiration 
values. Changes in respiration rates relative to resting respiration values were determined by 
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expressing the percent change in oxygen consumption rate relative to resting oxygen consumption 
rate. 
 
Figure 2-1 Schematic summary of oxygen consumption rate measurement 
Cells pre-treated with low glucose for 2 hours were incubated sequentially with (A): low glucose 
(2 mM glucose), (B) high glucose (16.7 mM final concentration), (C) 5 µM oligomycin, (D) 50 
µM 2,4-dinitrophenol and 25 mM pyruvate, and (E)  5 µM rotenone and 5 µM myxothiazol. 
Oxygen consumption rates were calculated for each period. Data used to indicate the activity of 
either spare respiratory capacity, or ATP synthesis, or proton-leak or non-mitochondrial 
oxygen consumption were derived from the difference of oxygen consumption rate between 
different periods as shown in figure. 
2.2.6 Real time PCR 
RNA isolation (Bio-Rad # 732-6820: Aurum
TM
 Total RNA mini kit), reverse transcription (Bio-Rad # 
170-8891: iScript cDNA synthesis kit), and real time PCR (Bio-Rad #172-5200: SsoFast
TM
 
EvaGreen® Supermix) analysis were performed on cell extracts from 832/13 cells to determine the 
mRNA levels of target. Gene expression levels were corrected by by cyclophilin E (Cyp) expression.  
2.2.7 Western blot 
Cellular proteins were extracted with cell lysis buffer (Cell Signaling #9803) containing 100× 
Protease Inhibitor Cocktail (Cell Signaling #5871). Extracts (40 µg) were resolved on pre-cast 
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INVITROGEN NuPAGE® Novex® 10% Bis-Tris polyacrylamide gels (Invitrogen #NP0301BOX) 
and electro-transferred to INVITROGEN Invitrolon™ 0.45 µm PVDF Membrane (INVITROGEN 
#LC2005). A polyclonal antibody against HIF-1alpha (Santa Cruz) was used as the primary antibody 
followed by horseradish peroxidase-conjugated anti-rabbit antibody (SIGMA A6154) to detect HIF-
1alpha. Similarly, γ-tubulin was detected by immunoblotting by a mouse antibody against γ-tubulin 
(SIGMA T6557) followed by horseradish peroxidase-conjugated anti-mouse antibody (Sigma 
A9917). Protein bands were detected with the Pierce™ ECL Western Blotting Substrate (Thermo 
Scientific 32106). 
2.2.8 Transfection of siRNA duplex  
siRNA duplexes were introduced into 832/13 cells at 50% confluence using Lipofectamine RNAiMax 
in compliance with the manufacturer’s instructions (Invitrogen). Experiments were performed 72 h 
after duplex transfection. 
2.2.9 Metabolites extraction and sample preparation 
Metabolite levels were assessed by gas chromatography-mass spectrometry (GC-MS) as previously 
described [319, 320]. After the insulin secretion assay, the cells were washed once with ice-cold PBS, 
scraped off the plates followed by centrifugation at 3,500 rpm for 1 minute at 4°C. The supernatant 
was discarded and the cell pellet was re-suspended in 100 μL water followed by sonicating for 60 
seconds (~40 KHz, ~140 W). 1 mL of cold methanol was added and followed by another 5 minutes 
centrifugation at 13,300 rpm. The supernatant was mixed with 5 μL of 0.25 mg/ml myristic acid-d27 
as an internal standard (IS; for retention time locking) followed by drying with nitrogen. 
Derivatization was then carried out in two steps: first, carbonyls were protected by methoximation 
using methoxyamine hydrochloride in pyridine at 50°C for 30 minutes. Second, acidic groups were 
silylated with 90 μL N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) with 1% 
trimethylchlorosilane (TMCS) at 50°C for 30 minutes. Both chemicals used for derivatization were 
from Sigma (St. Louis, MO). 
2.2.10 Metabolites measurement  
GC-MS was performed on an Agilent 7890A gas chromatograph coupled with a quadrupole mass 
spectrometer (5895C Agilent USA). 1 μL samples were injected in splitless mode using an Agilent 
auto sampler. The injector temperature was set at 250 ºC. Chromatography was performed on a two of 
  30 
15 m × 250 μm ×0.25 μm DB5-MS column with a phase thickness of 0.25 μm (J&W Scientific). The 
temperature program started isothermally at 50 ºC for 5 min, followed by a temperature ramp of 10 
ºC/min to 300 ºC where it was held for 10 min and run in backflush mode for another 15 min. The 
transfer line and ion source were both maintained at 250 ºC. The ionization energy of electron 
ionization (EI) was set to 70 eV and the data acquisition rate was 20 Hz with a scanning range of 50–
800 m/z. All samples were analyzed in a randomized order.  
2.2.11 Metabolomic data analysis 
Raw data files were exported to the Automated Mass Spectral Deconvolution and Identification 
System (AMDIS, Version 2.65) for smoothing, alignment and deconvolution of mass spectra. 
SpectConnect (http://spectconnect.mit.edu/) was used for spectra alignment. Target compounds were 
identified by matching both retention time and mass spectra in Fiehn GC-MS Metabolomics 
Retention Time Locking (RTL) Library (Version 2.0) or by only matching mass spectra in NIST 
library (2008). The GC/MS peak area is used as the abundance of metabolites and for further data 
analysis. Spectral data were normalized by the signal of internal standards (myristic acid d-27) and 
were exported to SIMCA P+ 12.0 software from Umetrics (San Jose, California). All metabolites 
variables were mean-centered, and UV-scaled. PCA was used to obtain an overview of the data and 
OPLS was used to relate the metabolic alterations to either the insulin secretion or other functions. In 
figures of metabolites profile, statistical significance was assessed by Student’s t test or by one-way 
or two-way analysis of variance for repeated.  
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Chapter 3 
Metabolomic Analysis of Pancreatic Beta Cell Insulin Release in 
Response to Glucose 
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3.1 Overview 
Defining the key metabolic pathways that are important for fuel-regulated insulin secretion is critical 
to providing a complete picture of how nutrients regulate insulin secretion. We have performed a 
detailed metabolomics study of the clonal beta cell line INS-1 832/13 using a gas chromatography-
mass spectrometer (GC-MS) to investigate potential coupling factors that link metabolic pathways to 
insulin secretion. Mid-polar and polar metabolites, extracted from the INS-1 832/13 beta cells, were 
derivatized and then run on a GC-MS. 355 out of 527 chromatographic peaks were identified as 
metabolites by our metabolomic platform. These identified metabolites allowed us to perform a 
systematic analysis of key pathways involved in glucose-stimulated insulin secretion (GSIS). Of these 
metabolites, 41 were consistently identified as biomarkers for GSIS by orthogonal partial least-
squares (OPLS). Most of the identified metabolites are from common metabolic pathways, including 
glycolysis, the sorbitol-aldose reductase pathway, the PPP, and the tricarboxylic acid cycle (TCA 
cycle), which suggests these pathways play an important role in GSIS. Lipids and related products 
were also shown to contribute to the clustering of high glucose sample groups. Amino acids lysine, 
tyrosine, alanine and serine were up-regulated by glucose whereas aspartate was down-regulated by 
glucose suggesting these amino acids might play a key role in GSIS. In summary, a coordinated 
signaling cascade elicited by glucose metabolism in pancreatic beta cells is revealed by our 
metabolomics platform providing a new conceptual framework for future research and/or drug 
discovery. 
3.2 Introduction 
As a key regulator of whole body metabolism, the hormone insulin is secreted by pancreatic beta cells 
as a response to an elevation in nutrients. Defective insulin secretion resulting from dysfunctional 
beta cells is a major determinant leading to the development of type 2 diabetes [328, 329]. 
Understanding how the beta cell secretes insulin is critical to developing novel therapies to treat type 
2 diabetes.  
A key metabolic pathway regulating insulin release involves an increase in the ATP/ADP ratio 
leading to an inhibition of ATP-sensitive K
+
 (KATP) channels, plasma membrane depolarization, 
activation of voltage-gated Ca
2+
 channels, and influx of extracellular Ca
2+
 that leads to insulin granule 
exocytosis [109]. This pathway, often referred to as the KATP channel-dependent pathway or 
triggering pathway, is unable to fully explain the mechanism of GSIS. Studies over the last several 
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decades have suggested that there is an unknown coupling mechanism that may act independently of 
KATP channels (referred to as the KATP channel-independent pathway or amplifying pathway) [109, 
330]. Strong evidence for the KATP channel-independent pathway(s) of GSIS has been provided by 
studies showing that glucose can still augment insulin secretion in islets from mice that lack 
functional KATP channels [60] or in conditions where the KATP channels are held open using diazoxide 
followed by membrane depolarization with high K
+
 [56]. Some potential coupling factors that may 
act in a KATP channel-independent fashion include GTP [331-333], glutamate [94, 334, 335], 
malonylCoA/ long-chain acyl-CoA (LC-CoA) [336, 337], and NADPH [49, 80, 81, 338]. 
Most of these candidate coupling factors were discovered using enzyme based reactions that can only 
measure one metabolite at a time. However, metabolism itself is a complex network of interdependent 
chemical reactions catalyzed by highly regulated enzymes. Since beta cells rely on metabolism to 
regulate insulin secretion, it is likely that multiple interconnected metabolic pathways are involved in 
this process. The discovery of the currently proposed candidate coupling factors was mainly based on 
manipulation of one single gene or enzyme, which could lead to false-positive or false negative 
observations. In some instances this has been demonstrated with the publication of contradictory 
results for some of these proposed coupling factors [151, 157, 158, 161, 334, 337, 339]. 
Thus, the intrinsic disadvantage of the current traditional methods used to study beta cell metabolism 
requires a more comprehensive and powerful method for reliable reconstruction of the metabolic 
networks in beta cells in response to experimental perturbations. This goal was, at least partially, 
fulfilled by the appearance of metabolomic platforms that simultaneously profiles (identify and 
quantify) a large array of metabolites [340]. 
GC-MS based metabolomics is one of the most efficient metabolomics platforms because of the high 
separation efficiency to resolve the complex biological mixtures, comprehensive databases and the 
good reproducibility [340-342]. As an integrated part of systems biology, metabolomics has certain 
advantages over other “omics” technologies, since metabolites are the end products of cellular 
biological process and their level ultimately reflects the most integrated response of a biological 
system. The net effect of genomic (~25,000 genes), transcriptomic (~100,000 transcripts) and 
proteomics (~1,000,000 proteins) is reflected in the net changes in metabolite levels in cells [169]. 
Although the concept of metabolomics has been successfully applied in a number of studies including 
diabetes research [343], the analytical techniques used in untargeted metabolomics still require further 
development. There is still a need for improved metabolite extraction methods that gives a better 
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yield of the diverse chemicals found in cells, improved handling of the wide-ranging concentration of 
analytes, and improved data mining software to assess the “information-rich” data sets [344]. 
In our study, a robust GC-MS based metabolomics strategy was applied to a clonal beta cell line INS-
1 832/13. An untargeted metabolomic analysis was performed to reveal critical metabolic pathways 
that could play a key role in beta cell stimulus secretion coupling. We show that glucose initiates a 
series of signaling cascades in beta cells and provide evidence for key up- and down-regulated 
pathways in beta cell metabolism. 
3.3 Results 
3.3.1 Insulin secretion 
Insulin secretion was assessed after incubating cells with low glucose (LG, 2 mM) or high glucose 
(HG, 16.7 mM) for 2 hours. As Figure 3-1 shows, LG treated cells had an insulin output of 129 ± 5 
µU insulin/mL/mg protein and HG treated cells had an insulin output of 793 ± 80 µU insulin/mL/mg 
protein. The fold increase in insulin output was 6.1 ± 0.6.  
 
Figure 3-1 Glucose stimulated insulin secretion in INS-1 832/13 beta cells.  
High glucose induced a six fold increase in insulin secretion. Cells were pre-incubated with 2 
mM glucose for 2×1 hour followed by 2 hour incubation with either 2 mM or 16.7 mM glucose 
before KRB medium was removed for insulin assay. Insulin concentration was normalized by 
protein amount. Results represent mean ± S.E. of three (n = 3) independent experiments for 
each condition. LG, low glucose (2 mM); HG, high glucose (16.7 mM). **, p<0.01 LG versus HG 
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3.3.2 Metabolite analysis by GC-MS 
Cells treated with either LG or HG were harvested followed by metabolite extraction and then 
assessed using GC-MS (GC-Quadrupole MS in EI scan mode). A typical total ion chromatogram 
(TIC) from 832/13 beta cells is shown in Figure 3-2A for LG and Figure 3-2B for HG. Figure 3-2C 
shows the net difference of chromatogram between LG and HG samples (LG chromatogram 
subtracted from the HG chromatogram). Figure 3-2C demonstrates that some chromatographic peaks 
were positive (increased in abundance) and others were negative (decreased in abundance). For 
example, peaks for pyruvate, succinate, fumerate, malate, alpha-ketoglutarate, dihydroxyacetone 
phosphate (DHAP), (iso)citrate, palmitate, glucose-6-phosphate (G6P) and 6-phosphoglucanate were 
all up regulated whereas aspartate was down-regulated in response to glucose. 
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Figure 3-2 Representative total ion current chromatogram (TIC) of metabolites  
The representative total ion current chromatogram (TIC) of metabolites isolated from (A) low 
glucose (LG) treated cells, (B) high glucose (HG) treated cells. (C) is (B)-(A) showing many 
metabolite levels are up-regulated by high glucose. Peaks showing metabolites of interested are 
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labeled in (C). Samples were run on GC/MS. GC gradient is running up to 30 min and retention 
time is depicted in minute. 
3.3.3 Metabolites identification  
Deconvolution of the data set by AMDIS identified 527 unique chromatographic peaks (putative 
metabolites) across all data sets. The Fiehn library identified 152 of the 527 peaks using retention 
time and mass spectra, and of these identified metabolites 101 were unique (51 of the identified peaks 
were from metabolites that had multiple derivatization products). The remaining 375 peaks were 
assessed using the NIST library resulting in the identification of an additional 302 metabolites. Of the 
302 identified metabolites 254 were unique metabolites (48 of the identified peaks by NIST were 
from metabolites that had multiple derivatization products). The remaining 73 peaks could not be 
identified using either the Fiehn or NIST libraries.  
3.3.4 Orthogonal projection to latent structures (OPLS) analysis 
We constructed an OPLS model that accounts for metabolic variations related to high glucose 
treatment of our cells. The model generated only one predictive component (PC1) that describes 92% 
of the variations in the X and Y matrixes (R
2
X = 0.92 and R
2
Y = 0.995). The R
2
X and R
2
Y values are 
a measure of fit, i.e. how well the model fits the X data set. The model also had three orthogonal 
components (R
2
X0 = 0.678). A large R
2
 (close to 1) indicates a good modeling, but it is not sufficient. 
The Q
2
 value indicates how well the model (X) predicts new data (Y). A large Q
2
 (Q
2
 > 0.5) indicates 
a good predictability. The model had an acceptable predictability of 93.5% (Q
2
 = 0.935). The 
orthogonal variation is likely composed of technical and biological variation not related to treating 
cells with either LG or HG. 
The score plot (Figure 3-3A) and the loading plot (Figure 3-3B) provide an overview of the OPLS 
model. For our single-Y OPLS model (a model that contains only one predictive component), the 
score plot shows the first predictive component (PC1) vs. the first orthogonal component in X (Figure 
3-2A, t1 vs. to1). The score plot shows clustering of the LG datasets and clustering of the HG datasets 
along t[1]. The loading plot (Figure 3-3B) illustrates which metabolites mainly account for the 
clustering seen in the score plot. In the loading plot, the metabolites positively (negative) furthest 
away from the origin of the coordinates along the first PC (X-axis) are considered biomarkers 
contributing most either positively (negatively) to GSIS. 
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Figure 3-3 Score and loading plots generated by OPLS on identified metabolites.  
(A) Score plot, ellipse is Hotelling T2 (95% confidence interval). (B) Loading plot. One Y-
predictive component and three orthogonal components were generated in this model. In score 
plot, samples were plotted against the score vector t[1] and to[1], and separated into two groups 
by t[1], which are corresponding low glucose and high glucose treated cells. No outliers were 
identified. Likewise, loading plot showed the individual influence of all variables on new latent 
variables.  
A
B
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Figure 3-4 Regression coefficient plots of metabolites potentially coupling glucose metabolism to 
insulin secretion 
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The regression coefficients are used for interpreting the influence of the variables in the X-
matrix (metabolites) on Y-matrix (insulin secretion) (n = 3). Metabolites that have high positive 
coefficient value are positively correlated to modeling. Analogous relationships hold for the 
items have significant negative coefficient value. Included are metabolites with coefficients that 
are either less than -0.015 or greater than 0.015. 
Figures 3-4 showed the coefficient value of 41 metabolites suggested to probably play a significant 
role in differentiating the 832/13 cells cultured at 2.0 mM glucose from those in 16.7 mM glucose. 
Among them, 6 were negatively associated with GSIS and included aspartate, adenosine, alpha-D-
glucosamine phosphate, inosine, serotonin and ketocaproic acid. The remaining 34 were positively 
associated with GSIS. 
3.3.5 Metabolic pathway analysis  
41 metabolites differentiated the response of the 832/13 cells cultured at LG from those cultured at 
HG (Figure 3-4). These metabolites belong to a number of metabolic pathways including glycolysis, 
TCA cycle, amino acid, fatty acid, PPP and sorbitol-aldose reductase pathway. The coefficient plot 
confirms that glycolytic intermediates play a critical role in the insulin secretion response of beta cells 
to glucose. Key glycolytic metabolites identified in the current set of data include G6P, DHAP, 3-
phosphglycerate and pyruvate (Figure 3-5).  
Anaplerosis, which is a net increase in TCA cycle intermediates, has also been suggested to play a 
key role in the metabolic regulation of insulin secretion [80, 81, 345]. Key TCA cycle metabolites, 
including (iso)citrate, alpha-ketoglutarate, succinate, fumarate, malate and trans-aconitic acid, were 
identified in our OPLS model (Figure 3-6). Oxaloacetate and succinyl-CoA were not detected in our 
experiments. These TCA metabolites also contributed significantly to the clustering seen in INS-1 
832/13 cells cultured at 16.7 mM glucose (Figure 3-3B). 
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Figure 3-5 Glycolytic metabolite levels are up-regulated by glucose 
Each biological sample has been pre-incubated with 2 mM glucose for 2×1 hr and then 
incubated with either 2 mM glucose (labeled as LG) or 16.7 mM glucose (labeled as HG).  The 
metabolites levels were normalized by internal standards (Myristic acid D-27). Peak 
identification and retention time in minutes: A) Glucose-6-phosphate at 21.598 min  B) 
Dihydroxyacetone phosphate at 15.6729 min C) 3-phosphoglycerate at 16.3969 min D) Pyruvate 
at 6.2946 min. Results represent mean ± S.E. of three (n = 3) independent experiments for each 
condition. **, p < 0.01 LG versus HG 
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Figure 3-6 TCA metabolite levels are up-regulated by glucose  
Each biological sample has been pre-incubated with 2 mM glucose for 2×1 hr and then 
incubated with either 2 mM glucose (labeled as LG) or 16.7 mM glucose (labeled as HG).  The 
metabolites levels were normalized by internal standards (Myristic acid D-27). Peak 
identification and retention time in minutes: A) (Iso)citrate at 16.5566 min B) Alpha-
ketoglutarate at 13.6546 min C) Succinate  at 10.1176 min D) Fumurate at 10. 6339 min E) 
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Malate at 12.4841 min F) Aconitate at 15.7555 min. Results represent mean ± S.E. of three (n = 
3) independent experiments for each condition. **, p<0.01 LG versus HG  
Interestingly, other metabolites were also strongly associated with insulin secretion as seen in our 
OPLS model coefficient plot (Figure 3-4), such as, the sorbitol-aldose reductase pathway 
intermediates sorbitol, fructose, and the PPP intermediates 6-phosphogluconate, ribulose 5-phosphate, 
ribose-5-phosphate (Figure 3-7). 
 
Figure 3-7 Aldose reductase and pentose phosphate pathway metabolites are up-regulated by 
glucose 
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Each biological sample has been pre-incubated with 2 mM glucose for 2×1 hr and then 
incubated with either 2 mM glucose (labeled as LG) or 16.7 mM glucose (labeled as HG).  The 
metabolites levels were normalized by internal standards (Myristic acid D-27). Peak 
identification and retention time in minutes: A) Sorbitol at 17.8669 min B) Fructose at 17.2064 
min C) Gluconate at 18.1216 min D) Phospholuconate at 22.5526 min E) Ribulose-5-phosphate  
at 19.6844 min F) Ribose-5-phosphate at 19.5758 min. Results represent mean ± S.E. of three (n 
= 3) independent experiments for each condition. **, p<0.01 LG versus HG 
 
Intermediates associated with fatty acid metabolism were also identified in our coefficient plot 
including palmitic acid, oleic acid, palmitoleic acid, glycerol-1-phosphate (Figure 3-8).  
  
Figure 3-8 Fatty acids are up-regulated by high glucose 
Each biological sample has been pre-incubated with 2 mM glucose for 2×1 hr and then 
incubated with either 2 mM glucose (labeled as LG) or 16.7 mM glucose (labeled as HG).  The 
metabolites levels were normalized by internal standards (Myristic acid D-27). Peak 
identification and retention time in minutes: A) Palmitic acid at 19.08 min B) Oleic at 20.771 
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min C) Palmitoleic acid at 18.867 min D) Glycerol-1-phosphate at 15.431 min. Results represent 
mean ± S.E. of three (n = 3) independent experiments for each condition. *, p<0.05; **, p<0.01 
LG versus HG 
 
 
Figure 3-9 Amino acid metabolite levels are changed by high glucose 
Each biological sample has been pre-incubated with 2 mM glucose for 2×1 hr and then 
incubated with either 2 mM glucose (labeled as LG) or 16.7 mM glucose (labeled as HG).  The 
metabolites levels were normalized by internal standards (Myristic acid D-27). Peak 
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identification and retention time in minutes: A) Tyrosine at 17.908 min B) Leucine at 7.81 min 
C) Alanine at 6.928 min D) Serine at 9.278 min E) Aspartate at 11.643 min F) Lysine at  17.712 
min. Results represent mean ± S.E. of three (n = 3) independent experiments for each condition. 
*, p<0.05; **, p<0.01 LG versus HG 
Amino acids leucine, lysine, tyrosine, alanine and serine were positively associated with clustering 
the INS-1 832/13 cell response to 16.7 mM glucose (Figure 3-9). On other hand, aspartate was the 
most negatively associated metabolite contributing to clustering of the response of INS-1 832/13 cells 
to 16.7 mM glucose (Figure 3-9).  The metabolic pathways that has been shown to be associated with 
GSIS as our OPLS model suggested was summarized in Figure 3-10. 
 
Figure 3-10 Metabolic signals identified by MVA to be correlated to insulin secretion  
Metabolites with coefficient value (> 0.015) are highlighted in green and are suggested by OPLS 
model to be positively correlated with glucose-stimulated insulin secretion. Metabolites with 
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coefficient value (< 0.015) are highlighted in red and are suggested by OPLS model to be 
negatively correlated with glucose-stimulated insulin secretion. DHAP: dihydroxyacetone 
phosphate. Glycerol-2-P: glycerol-2-phosphate 
3.3.6 Role of the PPP and sorbitol-aldose reductase pathway in regulation of insulin 
secretion 
Although the role of the PPP and sorbitol-aldose reductase pathway in insulin secretion is 
controversial [150, 346-349], metabolites involved in these two pathways are suggested to be 
positively associated to GSIS by our data. In order to assess the significance of flux through the PPP, 
the effects of pharmaceutical inhibitors and siRNA mediated knock-down are further tested.  
Two siRNAs against glucose-6-phosphate dehydrogenase (G6PDH), the first enzyme believed to be 
the rate-limiting step in the PPP, were used to assess the role of this enzyme in GSIS. The first siRNA 
(siG6PDH-1) and second siRNA (siG6PDH-2) both knockdown G6PDH mRNA by 60±5% and 
62±6% respectively (Figure 3-11A), however neither siRNA affected GSIS (Figure 3-11B).  
It is possible that blocking flux to both of these pathways may also affect insulin secretion so we next 
tried pharmaceutical inhibitors. 6-aminonicotinamide (6-AN), an inhibitor of the NADP
+
-dependent 
enzyme, 6-phosphogluconate dehydrogenase [350], and 2,5-Dihydro-4-hydroxy-5-oxo-1-
(phenylmethyl)-1H-pyrrole-3-carboxylic acid ethyl ester (EBPC), a specific inhibitor of the sorbitol-
aldose reductase pathway enzyme aldose reductase, were also used to inhibit the PPP. As compared to 
no treatment control or DMSO vehicle control, neither 6-AN, nor EBPC or even their combination 
had effect on GSIS in INS-1 832/13 cell line (Figure 3-11C). Different dosage and their combination 
had no effect on GSIS (data not shown). However, both 6-AN and EBPC increase insulin secretion in 
human (Figure 3-11D) and rat (Figure 3-11E) islets by more than 20 percent. More interestingly, 
insulin stimulated by the combination of 6-AN and EBPC was enhanced by one fold in human islets 
(Figure 3-11D) and 50 percent in rat islets (Figure 3-11E). 
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Figure 3-11 Role of the pentose phosphate and sorbitol-aldose reductase pathway in GSIS.  
(A) Gene expression of cells treated with two siRNAs (siG6PDH-1 and siG6PDH-2) directed 
against G6PDH (n = 5) for 72 hr. Both siRNAs duplexes decrease G6PDH RNA by 60 percent. 
(B) Effects of the two siRNAs against G6PDH on GSIS (n = 5). Neither siRNA duplex affects 
GSIS. (C) Effects of pentose phosphate inhibitor 6-AN (500 µM), aldose reductase inhibitor 
EBPC (50 µM), or a combination of 6-AN and EBPC on GSIS in INS-1 832/13 cell line (n = 5). 
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Neither of inhibitors nor their combination affects GSIS in INS-1 832/13 cells. Effects of pentose 
phosphate inhibitor 6-AN (500 µM), aldose reductase inhibitor EBPC (50 µM), or a 
combination of 6-AN and EBPC on GSIS in (D) human islets (n = 8) and (E) rat islets (n = 7). 
Both inhibitors and their combination increase GSIS in human and rat islets. Cells were treated 
with 6-AN and EBPC during the insulin secretion assay. Low glucose (LG), High gluocse (HG). 
*, p<0.05; **, p<0.01 non-treated versus treated. 
3.4 Discussion 
Although GSIS has been extensively studied, the biochemical pathways linked to insulin secretion 
have not been completely defined. In our study, an unbiased GC-MS based untargeted metabolomics 
approach was applied to INS-1 832/13 cells in order to gain insight into the metabolic regulation of 
insulin secretion. Overall, 527 chromatographic peaks (or potential metabolites) were detected of 
which 355 were identified as unique metabolites. Limiting the identification of unique metabolites 
from the 527 chromatographic peaks was partly due to the fact that some metabolites had multiple 
active functional groups that could be modified during the derivatization process. Using a 
combination of two libraries, the Fiehn library which identifies endogenous metabolites and the NIST 
library which identifies endogenous and exogenous metabolites, led to the identification of 355 
unique metabolites. The number of identified metabolites is larger than other studies of beta cells 
using similar techniques [333, 343, 351]. The most significant metabolites that differentiated low 
glucose treated cells from those treated with 16.7 mM glucose were identified by supervised pattern 
recognition using OPLS. Less than 8% of the information is lost during the analysis and there was 
only one principal component. Our OPLS model forms a good summary of the data set and has good 
predictability. Among all the metabolites detected by our system, 41 metabolites were found to be 
strongly associated with the metabolic response of cells to high glucose using our OPLS model. 
The unique metabolic phenotype of beta cells allows these cells to sense blood glucose levels. This is 
formed partly from the expression of a combination of glucose transporter 2 (high Km glucose 
transporter) and glucose phosphorylating enzyme glucokinase (hexokinase IV, GK) [352]. Glucose 
transporter 2 and glucokinase allow for a continuous flux of glucose carbon to enter glycolysis in a 
dose dependent manner. Glycolysis is the first key step in glucose sensing and it has been suggested 
that signals derived from glycolysis play a role in insulin secretion [49, 353]. As expected glycolytic 
intermediates, including G6P, dihydroxyacetone phosphate, 3-phosphglycerate and pyruvate, were 
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elevated in response to treating cells with 16.7 mM glucose and these glycolytic metabolites were 
strongly associated with GSIS in our OPLS model. 
In addition to increased glycolytic flux, several other cytosolic pathways were also shown to be 
associated with GSIS in our OPLS model. These pathways include the PPP, represented by 6-
phosphogluconate, ribulose-5-phosphate, ribose-5-phosphate, and the sorbitol-aldose reductase 
pathway (also known as the polyol pathway), represented by sorbitol and fructose in our 
metabolomics study. A key role for NADPH in regulating insulin release has been suggested 
(reviewed in refs [35, 49]) and the PPP is one pathway that may produce NADPH for modulating 
insulin secretion. The PPP plays a role in providing NADPH, ribose-5-phosphate for synthesis of 
nucleotides and nucleic acids, and erythrose-4-phosphate for synthesis of aromatic amino acids. The 
role of the PPP in insulin release is still being debated [150, 346-349]. The contribution of the PPP to 
total glucose utilization has been shown to be low in beta cells [33, 76, 354]. Also, the oxidative 
portion of the PPP contributes a relatively small amount of the total glucose oxidation rate [33]. It has 
been suggested that part of the reason for the low PPP activity in beta cells may be because of the 
glucose-stimulated increase in the cytosolic NADPH/NADP
+
 ratio [80, 84] which is thought to inhibit 
G6PDH (the flux-generating enzyme of the PPP) [355]. Since the activity of the PPP is low, it has 
been suggested that it contributes very little to the overall generation of NADPH [67] as compared to 
other NADPH producing pathways such as the pyruvate cycling pathways [35, 49]. However, the 
overall contribution of this pathway to NADPH production has not yet been directly studied. 
Interestingly, other studies have suggested that the PPP activity is dependent on glucose concentration 
and its enzyme transaldolase might be activated by glucose [286]. A recent paper has performed 
metabolomic studies on first phase insulin secretion in the INS-1 832/13 cells [148]. They focused on 
metabolites that changed in the first 15 minutes after the addition of high glucose. They also found 
that PPP intermediates were associated with insulin secretion. 
Intravenous (IVGTT) and oral glucose tolerance tests (OGTT) in patients with G6PDH deficiency 
showed that first phase insulin release was defective in these individuals [356]. Also more recently it 
has been shown that inhibition of G6PDH with siRNAs led to increased ROS, apoptosis, decreased 
proliferation, and impaired insulin secretion [349]. The impaired GSIS associated with long-term high 
glucose treatment of cells could be improved by overexpressing G6PDH [349]. G6PDH deficient 
mice had smaller islets and impaired glucose tolerance which suggests an important role for the PPP 
in beta cells [349]. Since our OPLS model also suggests that metabolites involved in PPP were 
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associated with GSIS and this is consistent with previously published studies [343], we performed 
further studies on the role of this pathway. Although the pharmaceutical inhibitor 6-AN affects GSIS 
in human islets, neither 6-AN changes insulin secretion in rat islets nor siRNAs against G6PDH alters 
the secretion function of INS-1 832/13 cells. Several reasons might contribute to this seemingly 
contradictory result. First, it could result from either the different permeability that different 
biological structures possess, or the physiological difference between species. The PPP activity in 
human islets was observed to be different from that in rat islets [149]. Second, it might be caused by 
the presence and absence of insulin in medium.  The PPP seems to contribute to secretory activity 
only if insulin is not accumulated in medium [348]. Last, the way how inhibitors were applied to cells 
might also play a certain role, because 6-AN was reported to disturb insulin secretion in pancreatic rat 
islets if they are pre-treated with this pharmaceutical inhibitor for six hours [150]. But in our 
experiment, 6-AN was not included for pre-treatment. Overall, the exact role of PPP in regulation of 
insulin secretion still needs further investigation.  
The sorbitol-aldose reductase pathway contributes only a small fraction to the total glucose utilization 
(both PPP and sorbitol-aldose reductase pathways do not exceed 10% of the overall glucose 
utilization [33]). Interestingly, the sorbitol-aldose reductase pathway enzyme, aldose reductase, which 
has a high Km value for glucose (20-200 mM) [357, 358] can be stimulated by ATP and inhibited by 
ADP by about ±20% over the physiological concentration range of these nucleotides [358]. Another 
sorbitol-aldose reductase pathway enzyme, sorbitol dehydrogenase activity is also favored by high 
glucose usually accompanied by lower NADH levels [169, 359]. Treating cells with high glucose 
likely stimulates the sorbitol-aldose reductase pathway since glucose stimulates an increase in the 
NAD
+
/NADH ratio in beta cells. The sorbitol-aldose reductase pathway has been shown to play a role 
in GSIS in some studies [360] and not in others [361, 362]. In one study, inhibitors of aldehyde and 
aldose reductases were shown not to inhibit GSIS or glucose metabolism in islets [361]. 
Overexpression of aldose reductase lead to a reduction of the NADPH/NADP
+
 ratio and this was 
associated with beta cell apoptosis [363]. In line with the above discussed evidence, our studies also 
suggest that this pathway is up-regulated in response to glucose in beta cells. However, it is unlikely 
this increase is relevant to insulin secretion since a specific inhibitor of aldose reductase does not 
inhibit GSIS.  
To date, the PPP and sorbitol-aldose reductase pathways have only been studied individually, even 
though there may be potential for cross-talk between these two pathways. The sorbitol-aldose 
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reductase pathway oxidizes NADPH whereas the PPP reduces NADPH which may allow both 
pathways to facilitate each other's activity through the cyclic use of NADPH. In addition, increased 
sorbitol-aldose reductase pathway activity could provide fructose for glycosylation and glycerol 
production which has been suggested to be important for GSIS [345, 364]. On one hand, if PPP 
supports GSIS by generating reducing equivalents, in the form of NADPH, or providing other 
precursor, like ribose-5-phosphate (R5P), for the synthesis of nucleotides and nucleic acids, inhibition 
of PPP could potentially lead to the decrease of GSIS. On the other hand, since there is significant 
glucose flux into these pathways, inhibition of both the PPP and the sorbitol-aldose reductase 
pathway may promote greater glucose flux through glycolysis and increase insulin secretion. 
Interestingly, we show that using inhibitors of both pathways does not inhibit insulin secretion in 
INS-1 832/13 cells, but did improve GSIS in both human and rat islets. The discrepancy between cell 
line and islets, as well as the exact role of PPP and sorbitol-aldose reductase pathways in regulation of 
GSIS remains to be elucidated. 
The role of lipids in GSIS is controversial. Numerous studies suggesting that glucose-stimulated lipid 
synthesis plays a role in insulin secretion [336, 365, 366] whereas other studies provide evidence 
against this hypothesis [160, 161, 321, 367, 368]. Most researchers in the area agree that intracellular 
levels of citrate, malonyl-CoA, palmitate and LC-CoA’s rise rapidly in beta cells exposed to elevated 
glucose concentrations. This evidence led to the proposed malonyl-CoA/LC-CoA hypothesis that 
states that PC mediated replenishment of oxaloacetate in the TCA cycle facilitates the accumulation 
and escape of citrate from the mitochondrial matrix into the cytosol for lipid synthesis. The role of 
lipids in GSIS is supported by our data showing that the levels of palmitic acid, oleic acid, palmitoleic 
acid and lauric acid are elevated by treating cells with 16.7 mM glucose and were also identified by 
our OPLS model as significant metabolites contributing to the clustering of high glucose treated cells.  
Amino acids, leucine, lysine, tyrosine, alanine and serine were also shown to contribute significantly 
to the clustering of high glucose treated cells in our OPLS model of insulin secretion. The 
significance of these amino acids in insulin secretion may be only to provide sufficient resources for 
insulin biosynthesis. However, it is also possible that they could be directly involved in regulating 
insulin release. Leucine is a known activator of glutamate dehydrogenase (GDH) [369] and an 
increased GDH activity has been suggested to play a key role in GSIS [370]. The elevated leucine 
levels seen in our studies provide further support for this role. One commonly mentioned amino acid 
associated with GSIS is glutamate. Glutamate was originally proposed as a potential coupling factor 
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linking glucose metabolism to insulin secretion [334]; however, this effect is controversial [339]. In 
our study glutamate was not a significant player in our OPLS model and in fact was negatively 
associated with insulin release. Less is known about the roles that alanine and serine play in GSIS. 
But our OPLS model suggests there may be a link. Interestingly, a role of these amino acids is 
supported by in vivo studies showing that alanine and serine induced a strong enhancement of insulin 
secretion as compared to other amino acids [371]. 
The most significantly reduced metabolite by high glucose treatment was the amino acid aspartate, 
which is consistent with previous studies [343, 347, 372]. Aspartate can be transaminated to 
glutamate by aspartate aminotransaminase. Aspartate aminotransferase plays a role in the malate-
aspartate shuttle which shuttles NADH from the cytosol into the mitochondrial matrix and is a key 
player in the regeneration NAD
+
 for maintaining flux through glycolysis. High glucose treatment of 
beta cells may reduce aspartate levels in part due to the higher demand on the malate-aspartate shuttle 
enzyme aspartate transaminase. Interestingly, the glycerol-phosphate shuttle metabolite 
dihydroxyacetone phosphate was also positively associated with GSIS in our OPLS model.  
Glycolysis-derived pyruvate enters the TCA cycle via one of two pathways, one involving pyruvate 
dehydrogenase (PDH) and the other involving PC. Pyruvate entering via PDH is oxidized to CO2 
generating NADH and FADH2 for ATP synthesis and pyruvate entering via PC is involved in net 
accumulation of TCA intermediates (anaplerosis) [33, 74, 75, 77]. All TCA intermediates were 
positively associated with insulin secretion in our OPLS model. Citrate/isocitrate, alpha-ketoglutarate, 
succinate, fumarate and malate were elevated by high glucose treatment of cells. The replenishment 
of TCA intermediates (PC mediated anaplerosis) appears to be of critical importance for beta cell 
glucose competence as 
13
C-NMR isotopomer analysis revealed that glucose responsiveness was more 
stringently associated to anaplerotic substrate flow as opposed to oxidative substrate flux [76]. 
Efficient knockdown of PC activity (by 50% or more) renders clonal beta cells and primary rat islets 
in a glucose unresponsive state without any changes in the glucose oxidation rate. Interestingly, PC 
activity was also reported to be reduced by at least 70% in human islets obtained from type 2 
diabetics [72]. 
The intrinsic disadvantage of the current traditional methods used to study beta cell metabolism 
requires a more comprehensive and powerful technology for reliable reconstruction of the metabolic 
networks in beta cells in response to experimental perturbations. In our metabolomics study, a 
potential limitation is the work uses the clonal cell line, 832/13 cells, in contrast to isolated islets. As 
  54 
an insulinoma cell line, INS 832/13 should have some specific metabolic activity like any other 
immortalized tumor cell does, such as cellular replication, which might mislead researchers by 
obscuring the real metabolic pathways involved in GSIS. To address this issue, further efforts will be 
made to upgrade our metabolomics study to animal or human pancreatic islets and results observed 
here will be compared to those seen in primary islets. However, the advantage of using the 832/13 
cells is that it is a homogenous preparation of beta cells as compared to islet preparations and 
obtaining sufficient number of cells is relatively easy. One of the key limitations of the metabolic 
platforms is the detection of low abundance metabolites and we feel that the current methodology 
presented here improves upon this and provides an important step towards making it easier to use 
isolated islets in metabolomics studies. However, there is still a need for improved metabolite 
extraction methods that gives a better yield of the diverse chemicals found in cells, improved 
handling of the wide-ranging concentration of analytes, and improved data mining software to assess 
the “information-rich” data sets [344].  
3.5 Conclusion 
Glucose metabolism plays multiple roles in the regulation of insulin secretion from beta cells. Most of 
the literature focuses on the role of glycolysis, ATP/ADP ratio, TCA cycle and anaplerosis in insulin 
secretion. However, other pathways may also be critical. For example, although it has been 
previously under-estimated in the past, our study suggests that the sorbitol-aldose reductase pathway 
and PPP might play an important role in beta cell stimulus-secretion coupling. There appears to be a 
coordinated effort in beta cells to increase the activity of a number of metabolic pathways in response 
to glucose; however, which pathways are critical for insulin secretion still needs to be investigated. 
The current metabolomics approach presented in this study allows one to assess the effects of 
perturbations to beta cell metabolism on most of the key metabolic pathways in a single assay. It is 
important to have broad assessment of these pathways in response to manipulating metabolic 
enzymes because of the complex metabolic interconnectivity seen in these cells. This integrating 
paradigm will provide a new conceptual framework for future research and drug discovery. 
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Chapter 4 
Assessment of the Metabolic Pathways Associated with the 
Second Phase Glucose-Stimulated Insulin Secretion 
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4.1 Overview 
Biphasic glucose-stimulated insulin secretion (GSIS) involves a rapid first phase followed by a 
prolonged second phase of insulin secretion. The biochemical signaling pathways that control these 
two phases of insulin secretion are poorly defined. In this study, we used a gas chromatography mass 
spectroscopy (GC-MS) based metabolomics approach to perform a global analysis of cellular 
metabolism during biphasic insulin secretion. A time course metabolomic analysis of the clonal beta 
cell line INS-1 832/13 cells showed that the second phase insulin secretion was negatively associated 
with hydroxyproline, proline, aspartate, glycine and lactate, and positively with both glycolysis 
(glucose-6-phosphate and dihydroxyacetone phosphate) and TCA cycle intermediates. Inhibition of 
TCA activity by UK5099, an inhibitor of the pyruvate carrier, selectively decreased second phase 
insulin secretion by 50 percent without altering the first phase insulin secretion in freshly isolated rat 
pancreatic islets. Our data suggest glycolysis derived anaplerosis via pyruvate carboxylase (PC) plays 
a central role in modulating the second phase insulin secretion. Overall, the insights provided by our 
study create a framework for planning future studies in the assessment of the metabolic regulation of 
biphasic insulin secretion. 
4.2 Introduction 
In vivo insulin secretion is biphasic, with a first-phase burst in insulin secretion occurring within the 
first 10 minutes after a glucose load and a subsequent second phase. The second-phase of insulin 
secretion may either reach plateau very quickly, as seen in mice, or show a progressively slow 
increase in insulin release reaching a plateau in next 2-3 hours, as seen in rats and humans [373]. 
Healthy human subjects have a biphasic insulin secretory response in vivo similar to that observed in 
perfused rat pancreas [374, 375], whereas isolated perifused human islets have a similar biphasic 
insulin response similar to that of perfused mouse islets [376-378]. 
The biphasic nature of insulin secretion seems to be critical for the regulation of postprandial glucose 
homeostasis. A role for the first phase insulin secretion is supported by studies from both dogs [125, 
126] and humans [110] showing that it likely plays a role in the regulation of postprandial glucose 
homeostasis by acting on the liver to inhibit endogenous glucose production [127]. In contrast, the 
second phase insulin release may play a role in inhibiting liver glucose production as well as 
promoting muscle glucose uptake and utilization [127]. Of these two functions of the second phase 
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insulin secretion, it has been suggested that the role in promoting muscle glucose uptake is more 
critical. 
Defects in both phases of insulin secretion, especially the first phase, may be the earliest detectable 
sign in individuals destined to develop type 2 diabetes [373]. Pre-type 2 diabetics have selective 
impaired first phase insulin secretion and this has been suggested to be an early warning of beta cell 
dysfunction [127, 128, 373]. However, how this defect occurs is unknown and in fact the biochemical 
mechanisms that control biphasic insulin secretion are still incompletely understood. 
The critical metabolic pathways that regulate biphasic insulin secretion are not known. One key 
glucose-derived signal in beta cells is a rise in the ATP:ADP ratio, which stimulates closure of ATP-
sensitive K
+
 (KATP) channels, resulting in plasma membrane depolarization, activation of voltage-
gated Ca
2+
 channels (VDCC) and Ca
2+
-mediated stimulation of insulin granule exocytosis [379, 380]. 
This so-called “KATP channel-dependent” mechanism appears to be particularly important in 
triggering exocytosis of a small number of granules from a plasma membrane-docked “readily 
releasable pool (RRP)” responsible for the first, acute phase of insulin release [65]. The PPP might 
also be implicated in control of the first phase insulin secretion as a recent study showed [148]. 
In contrast, in the second and sustained phase of insulin secretion, ATP and Ca
2+
 may play only 
limited or permissive roles, allowing other glucose-derived second messengers to come to the 
forefront [49]. Support for the “KATP channel-independent pathway” of beta cell glucose signaling 
comes from studies showing that glucose causes a significant increase in insulin secretion even when 
KATP channels are held open by application of diazoxide followed by membrane depolarization with 
high K
+
, or in animals in which the sulfonylurea receptor-1 (SUR1) K
+
 channel (a subunit of the KATP 
channel) was knocked out [58, 60, 64]. These and more recent studies suggest that mitochondrial 
metabolism of glucose generates signals, in addition to the changes in ATP:ADP ratio, that are 
important for the control of insulin secretion [49, 76, 81, 84, 321, 337, 381]. 
Since there is a lack of comprehensive data sets describing the metabolic activity of beta cells during 
the second phase insulin secretion, we used a metabolomics approach to gain more insight into how 
metabolic pathways integrate with the second phase insulin secretion. We developed an OPLS model 
[282, 286] to identify that key metabolites are strongly associated with the second phase insulin 
secretion. Our study shows that TCA intermediates seem to be the dominant modulator of the second 
phase insulin release.  
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4.3 Results 
4.3.1 Dynamic insulin secretion in INS-1 832/13 cells 
Dynamic insulin secretion was assessed after incubating the insulin secreting INS-1 832/13 cells with 
low glucose (LG, 2 mM) or high glucose (HG, 16.7 mM) for 0, 5, 10, 30 and 60 minutes. Insulin 
secretion in Figure 4-1 was expressed as the rate of insulin release, which was first normalized for 
protein concentration followed by subtracting the amount of insulin released at the previous time 
point and finally corrected for time. LG treated cells had a small peak at 5 minutes but overall had a 
minimal insulin response over the 60 minute time period (Figure 4-1A). HG treated cells had a 
biphasic insulin secretion with a peak reaching around 8 fold at 5 minutes followed by a sustained 
insulin response as long as glucose challenge stays (Figure 4-1A). This confirms that INS-1 832/13 
does possess biphasic characteristic in insulin release. 
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Figure 4-1 Time course glucose-stimulated insulin secretion and metabolome of 832/13 cells  
(A) Time-resolved insulin secretion in INS-1 832/13 cells. Insulin secretion rate was corrected 
for protein concentration and time in response to low glucose (2 mM) and high glucose (16.7 
mM). (B) OPLS model summary of metabolome from INS-1 832/13 cells collected at different 
times in first hour after glucose challenge (C) Metabolome profile recognized by OPLS score 
plot along the first and second components. Cells were first pre-cultured for 2 hours at 2 mM 
glucose followed by incubating cells at either 2 mM glucose or 16.7 mM glucose for 0, 5, 10, 30, 
or 60 minutes. Results represent mean ± S.E. of four (n = 4) biologically independent 
0
0.2
0.4
0.6
0.8
1
Comp[1]P Comp[2]P Comp[3]P
R2Y(cum)
Q2Y(cum)
B
C
  60 
experiments for each condition. Each sample was running twice on GC/MS. *, p < 0.05; **, p < 
0.01; ***, p < 0.001, LG versus HG 
4.3.2 Dynamic metabolome response to glucose challenge 
Following the insulin secretion assay, cell metabolites were extracted for analysis by GC-MS.  
Deconvolution of the mass spectra by AMDIS identified 325 unique peaks (potential metabolites) 
across the whole data set. The Fiehn library identified 102 of the 325 peaks and of these identified 
metabolites 73 were unique (29 of the identified peaks were from metabolites that had multiple 
derivatization products). The remaining 223 peaks were assessed using the NIST library resulting in 
the identification of additional 124 metabolites. Of the 124 identified metabolites 47 were unique. 
The remaining peaks could not be identified using either the Fiehn or NIST library.  
OPLS was constructed to overview the metabolome change in the first one hour after cells are 
challenged with glucose. As shown in Figure 4-1B, the model yielded three predictive (relevant to 
glucose challenge) and three orthogonal (unrelevant to glucose challenge) components, which can 
explain 93.7% (R
2
Y(cum)=0.937) information contained in original mass spectra data set and has a 
predictive power of 92.2% (Q
2
Y(cum)=0.922). The samples were proved to cluster according to first the 
time and then the concentration of glucose challenge. The scores loading (Figure 4-1C) shows 
samples quenched at 30 and 60 min are closer to each other, compared to those quenched at 5 and 10 
min. This reveals that metabolome change paralleled GSIS observed in INS-1 832/13 cells as shown 
in Figure 4-1A. 
4.3.3 Metabolome alteration associated with the second phase insulin secretion 
To understand the metabolic change of the second phase insulin secretion, an OPLS model was 
generated for data collected from samples quenched at 30 and 60 min, which corresponds to the 
second phase insulin secretion. As shown in Figure 4-2A, this model produced one predictive and one 
orthogonal components with 16.7% of the variation in the metabolome related to the time of 
quenching (R
2
X=0.216), which describe 97% (R
2
Y(cum)=0.97) variation and has a predictive power of 
96.8% (Q
2
Y(cum)=0.968). Samples collected from different time points are separated by the predictive 
component as shown in Figure 4-2B, which suggests that a distinct change of metabolome in second 
phase is likely anticipated.  
As the coefficient plot revealed (Figure 4-2C), all detected TCA intermediates, including alpha-
ketoglutarate, succinate, malate, fumarate, and (iso)citrate, were identified as positive biomarkers for 
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the second phase insulin secretion. Whereas, dihydroxyacetone phosphate (DHAP) and pyruvate had 
lower coefficient value, which suggests that they are less important to the second phase insulin 
secretion. The level of G6P almost did not change from 30 min to 60 min. That is probably why the 
coefficient value of G6P for the second phase is negligible (Figure 4-2C). Alanine, capric acid, 
palmitic acid and sedoheptulose anhydride monohydrate (Sedoheptulose AM) were also positively 
associated with the second phase insulin secretion as coefficient plot revealed. Hydroxyproline, 
proline, glycine, aspartate and lactate retained the negative effects on the second phase insulin 
secretion.  
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Figure 4-2 Multivariate analysis of metabolome responsible for second phase insulin secretion 
(A) OPLS model summary of the metabolomics data from INS-1 832/13 cells collected at 0, 30 
and 60 min. Only one predictive component was identified in new model. (B) OPLS score plot 
showing the grouping of samples collected at 0, 30 and 60 min along the first predictive and 
orthogonal component of an OPLS model. Cells were distributed along the first predictive 
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component and grouped into three clusters. (C) Coefficient plot showing the key metabolites 
positively associated with the second phase insulin secretion identified from Fiehn database. (D) 
Coefficient plot showing the key metabolites negatively associated with the second phase insulin 
secretion identified from Fiehn database. Results represent mean ± S.E. of four (n = 4) 
biologically independent experiments for each condition. Each sample was running twice on 
GC/MS. 
4.3.4 Metabolic pathway analysis 
Our study suggests that a number of key metabolites differentiated the metabolic response in the 
second phase insulin secretion to glucose in the INS-1 832/13 cells. These metabolites belong to a 
number of metabolic pathways. 
The coefficient plots confirm that glycolytic intermediates play a critical role in biphasic insulin 
secretion. Key glycolytic metabolites associated with the second phase insulin secretion include G6P, 
dihydroxyacetone phosphate, lactate and pyruvate (Figure 4-3). Treating cells with high glucose led 
to a rapid accumulation of G6P peaking at 30 minutes (Figure 4-3A). Interestingly, dihydroxyacetone 
phosphate showed a delayed accumulation taking 10 minutes before a difference could be seen as 
compared to control cells (Figure 4-3B). Pyruvate levels exhibited a time based linear accumulation 
with no peak up to 60 minutes (Figure 4-3C). Surprisingly, lactate levels showed a strong biphasic 
response to high glucose (Figure 4-3D).  
Key TCA cycle metabolites, including (iso)citrate, alpha-ketoglutarate, succinate, fumarate and 
malate, were identified to be associated with the second phase insulin secretion by our OPLS model 
(Figure 4-2). Oxaloacetate and succinyl-CoA were not detected in our experiments. (Iso)citrate, 
fumarate and malate showed a rapid rise in metabolite levels beginning at 5 minutes (the earliest 
measurement in these studies) (Figure 4-4A, B and C). (Iso)citrate and fumarate levels peaked at 
around 10 minutes whereas malate levels peaked at 30 minutes in response to treating cells with high 
glucose. Alpha-ketoglutarate and succinate levels showed a delayed response to high glucose that did 
not begin to rise until 10 minutes after treating cells with high glucose and a progressive rise for the 
duration of the experiment (Figure 4-4D and E). All of these TCA metabolites, particularly alpha-
ketoglutarate and succinate, showed a strong association to the second phase insulin release (Figure 4-
2C).  
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Figure 4-3 Time course responses of glycolytic metabolite levels  
Metabolites were isolated from INS-1 832/13 beta cells and run on GC/MS. Metabolites are 
identified by searching MS spectra against Fiehn library. The metabolites levels were 
normalized by internal standards (Myristic acid D-27). A) glucose-6-phosphate, B) 
dihydroxyacetone phosphate, C) pyruvate, D) lactate. (LG = 2 mM glucose; HG = 16.7 mM 
glucose) (n=4) *, p<0.05; **, p<0.01; ***, p < 0.001,  LG versus HG 
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Figure 4-4  Time course responses of TCA metabolite levels  
Metabolites were isolated from INS-1 832/13 beta cells and run on GC/MS. Metabolites are 
identified by searching MS spectra against Fiehn library. The metabolites levels were 
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normalized by internal standards (Myristic acid D-27). A) citrate/isocitrate (in our GC-MS 
system citrate and isocitrate are indistinguishable from each other), B) fumarate, C) malate, D) 
alpha-ketoglutarate, E) succinate. (LG = 2 mM glucose; HG = 16.7 mM glucose) (n=4). *, 
p<0.05; **, p<0.01; ***, p < 0.001,  LG versus HG 
 
Figure 4-5 Time course responses of other metabolites positively associated to second phase 
insulin secretion 
Metabolites were isolated from INS-1 832/13 beta cells and run on GC/MS. Metabolites are 
identified by searching MS spectra against Fiehn library. The metabolites levels were 
normalized by internal standards (Myristic acid D-27). A) Ribose 5-phosphate, B) 
Sedoheptulose anhydride monohydrate, C) Palmitic acid, D) Capric acid (LG = 2 mM glucose; 
HG = 16.7 mM glucose) (n=4). *, p<0.05; **, p<0.01 LG versus HG 
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Figure 4-6 Time course responses of amino acids 
Metabolites were isolated from INS-1 832/13 beta cells and run on GC/MS. Metabolites are 
identified by searching MS spectra against Fiehn library. The metabolites levels were 
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normalized by internal standards (Myristic acid D-27).  A) Hydroxyproline, B) Proline, C) 
Aspartate, D) Glycine, E) Alanine (LG = 2 mM glucose; HG = 16.7 mM glucose) (n=4). *, 
p<0.05; **, p<0.01 LG versus HG 
 
Other metabolites were also associated with biphasic insulin secretion as our coefficient plot 
suggested (Figure 4-5). Ribose-5-phosphate, an intermediate in the PPP, increased in response to high 
glucose and peaked at 10 minutes (Figure 4-5A). Other PPP metabolites were found not to change 
during the treatment of cells with high glucose (6-phosphogluconate, ribulose-5-phosphate and 
erythrose-4-phosphate, data not shown). Sedoheptulose anhydride monohydrate (Figure 4-5B) and 
capric acid (Figure 4-5D) had a rapid rise in metabolite levels peaking at 30 minutes. Palmitic acid 
(Figure 4-5C) showed no significant difference in the response to high glucose until the 30 minute 
time point. 
Alanine was the only amino acid positively associated with biphasic insulin secretion from INS-1 
832/13 cell (Figure 4-6E). On the other hand, hydroxyproline, proline (Figure 4-6A and B), aspartate 
(Figure 4-6C) and glycine showed a time based decrease and were revealed to be negatively 
associated with the second phase insulin secretion.  
4.3.5 Block of pyruvate influx selectively affects second phase insulin secretion  
Since TCA intermediates were identified as the most potent factors involved in the second phase 
insulin secretion by the metabolomics analysis, studies were done to further investigate the 
importance of glycolysis derived anaplerosis in biphasic insulin secretion. Mitochondrial pyruvate 
carrier sits at a critical junction between cytosolic generation of pyruvate in glycolysis and 
mitochondrial metabolism of pyruvate, which supplies anaplerosis with glucose-derived carbon. 
Using the specific inhibitor of mitochondrial pyruvate transport, UK5099, we found that both 100 µM 
and 150 µM UK5099 decreased the level of insulin secretion in the second phase by 50 percent (45 ± 
7% for 100 µM, 48 ± 0.3% for 150 µM) without altering the first phase insulin secreted from freshly 
isolated rat islets or the subsequent insulin secretion triggered by the combination of high glucose and 
KCl as shown in Figure 4-7. UK5099 also resulted in a reduction in mitochondrial pyruvate transport 
and metabolism (data not shown). 
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Figure 4-7 Effect of pyruvate inhibitors on biphasic insulin secretion in rat islets  
(A). Insulin secreted by perifused rat islets. Rat islets were perifused from 1 to 8 min with 2.8 
mM low glucose (LG) followed by 16.7 mM high glucose (time points from 9 – 40 min) and 
finally with 16.7 mM high glucose with 40 mM KCl (time points from 41– 60 min). (B). Area 
under the curve of the insulin secretion responses in A (basal, 1– 8 min; 1st phase, 9 –18 min; 
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2nd phase, 19 – 40 min; HG and KCl, 41– 60 min). Results represent mean ± S.E. of four (n > 3) 
independent experiments for each condition. **, p<0.01 non-treated versus UK5099 treated 
4.4 Discussion 
Although the biphasicity of insulin secretion in perfused pancreas and perifused islets has been a 
well-established physiological phenomenon [104-107] for the last two decades, the dynamic secretory 
response of pancreatic beta cell lines has received less attention than freshly isolated primary 
pancreatic beta cells. In fact, a clear biphasic feature in INS-1 832/13 cells [133, 382], but not in 
betaHC-9, HIT-T15 or INS-1 beta cells, was observed as a response to sustained elevated glucose 
stimulation. This biphasicity phenomenon in INS-1 832/13 cells was confirmed by our data (Figure 4-
1) since cell activity in the first ten minutes was distinctly different from what happens afterwards (up 
to 60 min) at both GSIS and metabolome levels. Hence, INS-1 832/13 cells were used in our study to 
investigate the coupling mechanism underlying dynamic insulin secretion. 
The profound difference of glucose responsiveness between different cell lines might be caused by a 
certain mechanism working independently of KATP channel, as the combination of 250 µM diazoxide 
and 40 mM KCl can evoke a biphasic response in INS-1 832/13 cells but not in HIT-T15 or INS-1 
[133]. The presence of KATP channel-independent (or amplifying) pathway probably involves the 
coupling of glycolytic and TCA cycle metabolic pathways paralleled by hypoxia-inducible factor 1 
alpha (HIF-1alpha)-mediated regulation of distal mechanism in insulin secretion signaling pathways 
[333]. Some other studies suggest that phospholipase C (PLC) / protein kinase C (PKC) pathway 
[121, 383-385] and/or cAMP [122] might be particularly important to the second phase insulin 
secretion, because the difference of nutrient-activated PLC isozyme expression [383] and inositol 
phosphate (IP) accumulation seem to be associated with species difference of the second phase 
insulin level between rat and mouse islets [386]. On the other hand, PKC activator tetradecanoyl 
phorbol acetate (TPA) [387],  and phorbol 12-myristate 13-acetate [388] are strong inducers of the 
sustained second phase insulin secretory response and can markedly increase the second phase 
response of mouse islets to glucose. However, islets isolation procedure [112], pre-stimulatory 
glucose level [113] as well as the length of pre-culture period [123] were later proved to contribute to 
the second phase of insulin secretion. The change of these experimental conditions could significantly 
improve the second phase response of mouse islets to insulin secretagogues.  
Up to now, no study has been done to investigate the mechanism specifically contributing to the 
second phase [383] or the relative importance of these potential pathways to different phases of 
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insulin secretion [148]. Our study attempted to fill this void by using untargeted metabolomics 
approach to obtain a broad profile of what happens metabolically in INS 832/13 beta cells during time 
course based stimulation. Since beta cells rely on metabolism to regulate insulin secretion it is likely 
that multiple interconnected metabolic pathways are involved in this process. The most significant 
metabolites that differentiated biphasic insulin secretion in response to high glucose were identified 
by OPLS. Among all the metabolites detected, some were found to be strongly associated with the 
metabolic response of cells to time course based stimulation as well as insulin secretion.  
All glycolytic intermediates were up-regulated by high glucose stimulation, but exhibited different 
kinetic characteristics. Glucose challenge led to a rapid accumulation of G6P peaking at 30 minutes. 
Pyruvate showed a time based linear accumulation with no peak up to 60 minutes. Pyruvate and 
NADH can be converted to NAD
+
 and lactate by lactate dehydrogenase (LDH). In this process, NAD
+
 
is regenerated to maintain flux through glycolysis. Lactate was shown to accumulate with time in our 
studies and its response appeared to be biphasic suggesting that some of the glycolysis derived 
pyruvate in beta cells is diverted away from mitochondrial entry. This is consistent with previously 
published studies using the INS-1 832/13 cells [148, 382]. 
Pyruvate links upstream glucose metabolism in glycolysis to the downstream generation of metabolic 
signaling molecules involved in regulating insulin release. Most of the pyruvate generated by 
glycolysis is directed towards metabolism in the mitochondrial TCA cycle. Islet beta cells have two 
key mitochondrial enzymes involved in pyruvate metabolism, PC and pyruvate dehydrogenase (PDH) 
[33, 75-77]. Pyruvate entering the TCA cycle through the PDH reaction leads to the generation of 
ATP that modulates KATP channels whereas pyruvate metabolism through the PC reaction leads to an 
increase in TCA intermediates (called anaplerosis).  TCA cycle intermediates detected by our GC-
MS, including (iso)citrate, alpha-ketoglutarate, succinate, fumarate and malate, were identified by our 
OPLS model as key components strongly associated with the second phase insulin secretion (Figure 
4-2C). The levels of these metabolites were noticeably raised during the second phase of insulin 
secretion (Figure 4-4).  Interestingly, alpha-ketoglutarate and succinate levels did not begin to rise 
until around 10 minutes after stimulating the cells, followed by a progressive rise with time. That’s 
probably why both alpha-ketoglutarate and succinate showed the strongest association with the 
second phase insulin secretion.  Our data suggests anaplerosis is likely involved in regulating the 
second phase insulin secretion. 
In order to investigate the importance of anaplerosis to biphasic insulin secretion, UK5099 [389] was 
used to inhibit the influx of pyruvate from cytoplasm to mitochondria in rat islets.  UK5099 is an 
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inhibitor of mitochondrial pyruvate carrier which specifically modifies a thiol group on the carrier. It 
is able to cause a reduction in mitochondrial pyruvate transport and metabolism (data not published 
yet). Figure 4-7 showed that UK5099 had a preference to decrease the second phase of insulin 
secretion in rat islets and this inhibition effect was reversible. Additionally, the ability of rat islets to 
respond to insulin secretagogues was not affected once UK5099 was eliminated from the perifusion 
buffer. The selective inhibition of the second phase insulin secretion by UK5099 suggests that if 
glucose-derived carbon supply is limited, the proportion of pyruvate flux into TCA as acetyl-coA 
through pyruvate dehydrogenase takes precedence over anaplerosis through pyruvate carboxylases to 
maintain the basal level of insulin secretion as well as other basic ATP-dependent activity critical for 
cell survival. This phenomenon indicates that anaplerosis as part of the KATP independent pathway, 
rather than ATP generation, might be the dominant factor underlying the second phase insulin 
secretion, which is in agreement with the previous study done by Straub [133]. 
Among all TCA cycle intermediates, alpha-ketoglutarate deserves our special attention for two 
reasons. First, alpha-ketogutarate links pyruvate metabolic fate to insulin secretion through pyruvate-
isocitrate cycling [49, 82]. Second, alpha-ketoglutarate functions as an essential component of 
reactions catalyzed by alpha-ketoglutarate dependent hydroxylases [390], which facilitates oxidative 
decomposition of alpha-ketoglutarate leading to generation of CO2, succinate, active oxygen species 
and hydroxylated substrate. One of the first identified substrates is proline. The hydroxylation of 
proline by prolyl hydroxylase might be involved in regulation of insulin secretion through both 
hypoxia inducible factors 1 alpha (HIF-1alpha) -dependent [96] and -independent [95] mechanisms. 
The latter is also confirmed by data from our group (data not published yet). Hydroxyproline, the 
hydroxylation product of proline, is negatively associated with the second phase insulin secretion. An 
increase of alpha-ketoglutarate occurs simultaneously with a decrease in hydroxyproline which may 
indicate alpha-ketoglutarate mediated proline hydroxylation is one important coupling pathway 
modulating the second phase insulin secretion. Since the selective inhibition of UK5099 on the 
second phase insulin secretion in rat islets perifusion is acute and reversible, its effect on biphasicity 
of insulin release is most likely through an HIF-1alpha-independent mechanism (data not published 
yet).   
Glucose increased ribose-5-phosphate peaking at 10 minutes, which is in a good agreement with 
another study showing that PPP potentially plays a role in the first phase insulin secretion [148]. 
Interestingly, other PPP metabolites were found not to change in response to high glucose (ribulose-5-
phosphate and erythrose-4-phosphate, data not shown). Our data suggests that the upstream oxidative 
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arm of the PPP (specifically the activity of glucose-6-phosphate dehydrogenase (G6PDH)) was up-
regulated in response to glucose, however, downstream products were generally not altered. The 
significance of selective up-regulation of the G6PDH activity, but not other parts of the PPP, has not 
been shown before, possibly because the PPP serves to provide ribose-5-phosphate for the synthesis 
of nucleotides and nucleic acids.  
In addition, the hexosamine biosynthesis pathway metabolite N-acetylglucosamine (data not shown) 
identified from NIST library was also shown to rise rapidly with glucose treatment (data not shown), 
which is consistent with its potential role in regulating insulin secretion [391]. The reason why 
alanine, sedoheptulose anhydride monohydrate, palmitic acid and capric acid are indicative of second 
phase insulin secretion remains unresolved. Another interesting aspect of the current set of studies is 
that a number of metabolites were consistently down-regulated during the second phase insulin 
secretion. These include proline, aspartate, and glycine. In many organisms, proline is believed to act 
as a stress protectant by serving multiple functions: protein and membrane stabilization, lowering the 
Tm of DNA, and scavenging of reactive oxygen species [392]. Although its function as a universal 
antioxidant in mammalian systems is relatively unexplored, proline is suggested to scavenge 
intracellular ROS in mammalian cells [393] and thereby inhibit ROS-elicited apoptosis in various 
cancer cell lines [394, 395]. If that endogenous proline is, in fact, a ROS scavenger and the inverse 
relationship between proline content and ROS levels also exists in pancreatic beta cells, our data 
imply that anti-oxidative defense mechanisms of pancreatic beta cells are particularly weak (the 
expression levels of antioxidant enzymes such as superoxide dismutase, catalase, and glutathione 
peroxidase are known to be very low in islets compared with other tissues [396]) and can be easily 
overwhelmed by the redox imbalance arising from overproduction of reactive oxygen and nitrogen 
species [397, 398]. The significance of the reduction of these metabolites as it relates to biphasic 
insulin secretion is unknown and is currently under investigation in our laboratory.  
4.5 Conclusion 
In the current study we showed that a number of metabolites were associated with second phase 
insulin secretion. Of all candidates, alpha-ketoglutarate, succinate and other TCA cycle intermediates 
were the metabolites strongly associated with second phase insulin secretion. Hydroxyproline, proline 
and aspartate were negatively correlated with second phase insulin secretion. This evidence indicates 
that alpha-ketoglutarate mediated proline hydroxylation is probably central for the second phase 
insulin secretion.  In conclusion, our study provides a good overview of the metabolic changes that 
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occur during second phase insulin secretion and offers valuable insights into the understanding of the 
metabolic effects of glucose in beta cells. 
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Chapter 5 
Mechanistic Study of Time-Dependent Effects of Glucose on 
Insulin Secretion 
  
  76 
5.1 Overview 
Glucose-stimulated insulin secretion (GSIS) of primary pancreatic beta cells is determined by the net 
balance between the acute stimulation-secretion coupling generated by the concomitant stimuli that 
cells are currently exposed to, and time-dependent effects (TDEs) elicited by previously applied 
insulin secretagogues. TDEs can be either inhibitory or potentiating. Their interaction is believed to 
form the biphasic slope of insulin release. In this study, the regulatory process governing the 
dynamics of insulin release was investigated using a gas chromatography mass spectroscopy (GC-
MS)-based metabolomics approach. Our data reveal that time-dependent inhibition (TDI) at the 
insulin secretion level probably exists, but is neutralized by an opposing effect in our INS-1 832/13 
cell line, and the secretory activity of pancreatic beta cells actually results from the integrated reaction 
between acute stimulation-secretion coupling and its memory of previously applied stimuli. 
Multivariate analysis (MVA) identified statistically significant alterations in the levels of 19 
metabolites, which are involved in both glucose cytosolic and mitochondrial metabolism. Our data 
showed that the TDI effect is probably mediated by the redox state of beta cells, represented by the 
NAD
+
/NADH ratio generated by glycerol-phosphate shuttle and malate-aspartate shuttle activity as 
well as lactate output and proline level. In fact, the level of these intermediates is strongly affected by 
the duration of the pre-culture period. On the other hand, time-dependent potentiation (TDP) might be 
mediated by 3-phosphoglycerate and citrate-induced hyper phosphorylation of regulatory proteins 
involved in insulin exocytosis of pancreatic beta cells. Overall, our data suggest that the upstream 
glycolytic pathway can mediate the TDI effect observed in the INS-1 832/13 cell line and that the 
proximal part of stimulation-secretion coupling might be responsible for time-dependent potentiation.  
5.2 Introduction 
As a major insulin secretagogue, glucose can not only promote the acute insulin secretion, but also 
induce a memory of pancreatic beta cells for previous glucose challenge. A major difference between 
the acute glucose stimulatory effect and beta cell memory is that the latter does not require the 
continuous presence of insulin secretagogue and will last for a certain period of time even after 
insulin secretagogue is removed from medium. This phenomenon, which is also called time-
dependent effects (TDEs), was first reported by Grodsky, G.M. [105-107] and Nesher and Cerasi 
[139-142]. TDEs refer to  the observation that repeatedly challenged pancreatic beta cells can develop 
either an enhanced (time-dependent potentiation or TDP) [104, 106, 119, 131, 140, 143-146] or 
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impaired (time-dependent inhibition or TDI) [119, 143, 144, 146] response to subsequent stimulation. 
The type and magnitude of subsequent insulin responses depend on the type of secretagogues and the 
condition of exposure, including the concentration (dose dependent) of secretagogues and the 
duration (time dependent) of the stimulation applied: high concentrations and long durations generate 
amplification of the subsequent insulin responses, while low concentrations and short pulses of 
stimulation tend to induce a refractory state [104-107, 119, 131, 139-145]. 
TDEs offer a flexible mechanism to modulate GSIS and adapt pancreatic beta cells to environmental 
changes by promptly sensing the energy status and by altering the insulin secretion rate in a timely 
manner. The signaling cascade of TDEs is, hence, an ideal pharmaceutical target of type 2 diabetes 
therapy. In addition, TDEs were suggested to be the underlying mechanism for biphasic insulin 
secretion, because a tight correlation was discovered between the magnitude of TDP and the slope of 
second-phase insulin response [144].  The biphasic insulin release was believed to reflect the effect of 
the net balance between TDP and TDI on the acute stimulation [147].  TDEs hypothesis does not 
contradict either the pool-model [105, 106, 131, 132] or the signal-modulation hypothesis. Indeed, the 
TDEs hypothesis perfectly fits into both models [111]. 
Currently, it is known that both TDP and TDI effects are determined by glucose metabolism, and 
neither cyclic AMP [399] nor polymerization of tubulin [400] is involved in this process. However, 
significant differences seem to exist between the characteristic of TDP and TDI. First, TDP 
generation is calcium dependent [146], while TDI is not [401]. Second, duration of the TDI effect has 
been observed to last longer than TDP [120]. Third and last, they affect insulin secretion in different 
ways. TDP augments insulin release by acting on velocity [401], while TDI appears to change Km 
(enzyme substrate concentration at which the reaction rate is half of Vmax) of the response [402]. 
Although anaplerotic input [403] and involvement of nitric oxide synthase [404] have been suggested 
to be sufficient to elicit glucose-induced TDP, not much has been discovered about TDI, and its 
mechanism remains to be further investigated.  
Here, a robust GC-MS based untargeted metabolomic analysis was applied to study the mechanism of 
glucose-induced time-dependent effects and their potential roles in biphasic insulin release of INS-1 
832/13 cell line. 
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5.3 Results 
5.3.1 Glucose stimulated insulin secretion (GSIS) showing time dependent effects  
GSIS was done by pre-culturing INS-1 832/13 cells in KRB medium with 2 mM glucose for different 
periods of time as indicated in figure legend before exposure to non-stimulating and stimulating 
glucose. As Figure 5-1A shows, although a 70 percent decrease of insulin secreted by cells cultured in 
basal level glucose was observed as pre-culture time extended from one hour to three hours, the 
insulin released in the first hour remained the same for cells incubated with stimulatory levels of 
glucose. The discrepancy between two different conditions indicates either a lack of TDI or an 
opposite effect elicited by stimulatory level glucose, which can neutralize the TDI effect observed in 
low glucose treated cells. If TDI is completely absent at stimulatory glucose levels, a steady and 
stable insulin secretion rate should always be observed, despite pre-treatment duration. On the 
contrary, the presence of an opposing effect should be characterized by a time-dependent secretion 
pattern. To distinguish between these two possibilities, insulin secreted in the first 10 minutes was 
collected and plotted. As shown in Figure 5-1B, with longer pre-culture time, more insulin was 
released by beta cells, which clearly suggests that a TDI effect existed, but was overcome quickly by 
a potentiation mechanism in stimulating glucose treated beta cells. Although TDI was also reported to 
last longer than TDP [111], this potentiation effect is predicted to last equally long in order to 
neutralize the TDI effect, which should be reflected at the metabolome level if they retain different 
mechanisms. As TDP possesses different characteristics from TDI [120, 146, 401-404], distinctive 
coupling factors might be anticipated, enabling us to perform a metabolomic study of beta cells.  
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Figure 5-1 Glucose-stimulated insulin secretion showing time-dependent effects  
INS-1 832/13 beta cells was pre-cultured with 2 mM glucose for different periods of time and 
exposed to either 2 or 10 mM glucose for (A) 1hr or (B) 10 minutes before insulin was measured 
by radioimmunoassay. Insulin secretion corrected for protein concentration. Results represent 
mean ± S.E. of four (n = 8) independent experiments for each condition. **, p<0.01; ***, p < 
0.001, cells pre-treated for 1hr versus either 2hr or 3hr 
5.3.2 Metabolite detection and identification 
Following a one hour culture period with KRB and subsequent insulin assay, cells were harvested and 
metabolites were extracted and assessed using GC-MS (GC-Quadrupole MS in EI scan mode). The 
representative total ion chromatogram (TIC) of metabolism from INS-1 832/13 beta cells is shown in 
Figure 5-2(A-D). Figure 5-2(E-F) shows the net difference of TIC generated by cells pre-cultured in 
non-stimulating glucose for 1 or 3 hour, but incubated in either non-stimulating (Figure 5-2E) or 
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stimulating (Figure 5-2F) glucose. These data suggest that a longer pre-culture period will reduce the 
quantity of a few metabolites (Figure 5-2E), which agrees with the observation of insulin secretion in 
Figure 5-1A and further confirms that the metabolism activity cultured in non-stimulating glucose 
conditions decreases along pre-stimulatory time. Additionally, despite the seemingly unaffected 
insulin response in high glucose treated cells, many metabolites are, in fact, up-regulated by glucose 
as pre-culture time persists (Figure 5-2F). This strongly suggests that the failure to observe TDI at the 
insulin secretion level in high glucose condition is probably due to the neutralization of TDI by its 
opposite effect, rather than being caused by an actual deficiency of TDI. 
 
Figure 5-2 Representative total ion current chromatogram (TIC) of metabolome in INS-1 
832/13 beta cells showing time-dependent effects.  
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(A) Representative TIC for the metabolome isolated from INS-1 832/13 beta cells pre-cultured 
for 1 hr in low (2mM) glucose (LG). (B) Representative TIC for the metabolome isolated from 
INS-1 832/13 beta cells pre-cultured for 1 hr high (10mM) glucose.  (C) Representative TIC for 
the metabolome isolated from INS-1 832/13 beta cells pre-cultured for 3 hr in low (2mM) 
glucose (LG). (D) Representative TIC for the metabolome isolated from INS-1 832/13 beta cells 
pre-cultured for 3 hr in high (10mM) glucose.  (E) 1 hr LG TIC subtracted from 3 hr LG TIC. 
(F) 1 hr HG TIC subtracted from 3 hr HG TIC. 
Deconvolution of the mass spectra by AMDIS identified 459 unique chromatographic peaks 
(potential metabolites) across all data sets. The Fiehn library identified 86 unique metabolites using 
retention time and mass spectra. The remaining 304 peaks were assessed using the NIST library 
(based only on mass spectra) resulting in the identification of an additional 292 compounds. The 
remaining 81 peaks could not be identified in either the Fiehn or NIST libraries. 
5.3.3 Multivariate analysis 
An OPLS model was created to analyze our mass spectra (MS)-based metabolomics data and to 
identify the significant metabolites or metabolic pathways that might play an important role in 
mediating glucose-induced TDE. As Figure 5-3A suggests, three predictive components and two 
orthogonal components were generated in our model. This model can describe 96.1% 
(R2Y(cum)==96.1%) of variations in our data set and have almost equally good predictability 
(Q2Y(cum)= 94.4%). The remaining variations are likely composed of technical and biological 
variations, which are possibly not relevant to our model.  
In the score plot (Figure 5-3B), which shows new variables computed as linear combinations of 
original variables to provide a summary of our data set, cells are grouped according to the 
concentration of second stimuli (low or high glucose) and the duration of the first pulse (Figure 5-
3C). The group of non-stimulating glucose treated cells distributed evenly along the second 
component. However, the group of stimulatory glucose treated cells further clustered into two 
different sub-groups along PC2, where the 1hr group was much farther away from both 2hr and 3hr 
groups. Again, this phenomenon doesn’t match their corresponding insulin secretion observed in 
Figure 5-1, but supports the idea that a potentiation mechanism exists and acts to oppose and 
neutralize the TDI effect. 
The loadings are the weights with which the X-variables are combined to form the X-scores. Figure 
5-3C represents the importance of the metabolites in the selected component and hence reveals which 
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metabolites show the correlation structure or describe the similarity and dissimilarity between our 
samples. As Figure 5-3C shows, insulin secretion dominates the first principal component and pre-
culture duration nearly dominates the second principal component. The pre-cultured time period is 
negatively correlated to insulin secretion in component 1. The loading plot (Figure 5-3C) illustrates 
which metabolites mainly account for this clustering along the corresponding principal component. 
Thus, those metabolites farthest away from the origin of the coordinates along the first PC could be 
considered as biomarkers for GSIS and, similarly, those along the second PC could be considered to 
contribute to TDE.  
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Figure 5-3 Orthogonal projection to latent Structures (OPLS) analysis on metabolome showing 
time-dependent effects  
C
D
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(A) Model overview to show the summary of the fit of the model. The figure displays cumulative 
R
2
Y(cum) (fraction of the variation of the data explained by each component) and cumulative 
Q
2
Y(cum) (fraction of the information of the data predicted by each component in new model). 
The two Y (insulin and pre-treatment) are correlated and are summarized by three new 
predictive variables, the scores t1 to t3, explaining 96% of the variation. (B) Score plot of t1 vs. 
t2 to show the observations cluster in different groups. Each group represents a setting of the 
experimental design. The ellipse represents the Hotelling T2 with 95% confidence.  The scores 
t1 and t2, one vector for components 1 and 2, are new variables computed as linear 
combinations of all the original variables to provide a good summary of our samples. No 
obvious outliers are present in our data. The score plot shows that low glucose (LG)-treated 
samples are separated from high glucose (HG)-treated samples by t1 and then they are further 
separated into 3 different sub-groups by t2 based on the pre-treatment time. 2hr, 3hr and high 
glucose treated group diffuses from 1 hr and high glucose treated group. (C) Loading plot of 
component 1 vs. component 2 used to show which variables describe the similarity and 
dissimilarity between groups. Metabolites close to insulin secretion (one Y variable) are positive 
correlated to insulin secretion and those far away from insulin secretion are negatively 
correlated to insulin secretion. Our data set shows that some metabolite with both high weight 
on component 1 and component 2 are correlated to both insulin secretion and pre-treatment 
(another Y variable). Some other metabolites only with high weight value on component 1 are 
more correlated to pre-treatment than insulin.  (D) Coefficient plot summarizes the relationship 
between the Y variables (insulin secretion and pre-treatment) and the X variables (metabolites). 
X-axis represents coefficient over insulin secretion and Y-axis represents coefficient over pre-
treatment. The metabolites with the highest or lowest X values are either positive or negatively 
correlated to insulin, and vice versa. Msetabolites with the highest or lowest Y values are either 
positive or negatively correlated to pre-treatment. 
The loading plot shown in Figure 5-3C, however, only reveals the correlation structure between 
metabolites and samples along the first two PCs. In order to get a complete picture of the 
metabolomic data, a coefficient plot is generated in Figure 5-3D, in which the coefficient over insulin 
secretion is plotted as the x-axis and the coefficient over pre-culture duration is plotted as the y-axis. 
The coefficient summarizes the relationship between our samples and metabolites over all principal 
components. The metabolites farther away from the origin of the coordinates along the axis could be 
considered as the biomarkers contributing more to that factor. Our coefficient plot (Figure 5-3D) 
  85 
shows that, almost all TCA cycle intermediates and most glycolytic metabolites are more correlated 
to insulin secretion, since they have high positive x-values and low y-values. Likewise, 3-
phosphoglycerate and dihydroxyacetone phosphate are metabolites which are suggested (either 
positively or negatively) to correlate to TDE as shown in Figure 5-3D. Ribose-5-phosphate and 
alanine might also negatively correlate to the TDE. There are still some other potential coupling 
factors, however, they are not listed in our figure because either their function or their names are 
unknown. 
 
5.3.4 Coupling factors of time-dependent effect 
The metabolites identified in our study are involved in almost 30 metabolic pathways, such as 
glycolysis, TCA cycle, PPP, amino acid, fatty acid and nucleotides metabolism.  
As shown in Figures 5-4, glucose-6-phosphate, dihydroxyacetone phosphate (DHAP), 3-
phosphoglycerate and lactate are all correlated with both GSIS and the TDE. The level of some 
metabolites increased with a longer pre-culture duration, approximately by 67.9% (± 9.5%) for 
glucose 6-phosphate and 156% (± 12.1 %) for 3-phosphoglycerate. The level of others decreased as 
pre-culture time persisted, approximately by 80.8 % (± 5.3%) for DHAP and 51.5 % (± 10.6%) for 
lactate. As multivariate analysis (MVA) suggested, DHAP and 3-phosphoglycerate, either negatively 
or positively associated with TDE, were actually the most significant metabolic intermediates.   
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Figure 5-4 Time-dependent effects revealed by glycolytic intermediates 
Metabolites are isolated from INS-1 832/13 beta cells, run on GC/MS and identified by 
searching spectra against Fiehn library. The metabolites levels are normalized by internal 
standards (Myristic acid D-27). A) Glucose-6-phosphate, B) dihydroxyacetone phosphate, C) 3-
phosphoglycerate, D) Pyruvate, E) Lactic acid. (LG = 2 mM glucose; HG = 10 mM glucose) 
(n=4). 1 hr LG versus 2hr or 3hr LG #, p <0.05; ##, p <0.01; 1 hr HG versus 2hr or 3hr HG *, p 
<0.05; **, p <0.01. 
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All TCA cycle intermediates also positively contributed to the clustering of samples along insulin 
secretion, a finding which was in line with all previous studies [319, 320, 343]. However, in terms of 
their relationship to TDE, the TCA cycle seems to be split into two mini-cycles. The first half cycle, 
represented by citrate and alpha-ketoglutarate, was positively correlated with TDE, since metabolite 
levels were up-regulated (40 percent for alpha-ketoglutarate and 140 percent for citrate) in cells 
treated with stimulatory glucose as pre-stimulatory period extended. The second half cycle, 
represented by succinate, fumarate and malate, was negatively correlated with TDE, since the 
intermediates’ levels were down-regulated by 54 percent for succinate, 57 percent for fumarate and 
75 percent for malate along pre-stimulatory duration in cells treated with non-stimulatory glucose.  
In addition to glycolysis, another glucose cytosolic metabolism pathway---the PPP---represented by 
gluconate, 6-phosphogluconate and ribose-5-phosphate in our study, was correlated with both insulin 
secretion and the pre-stimulatory period. The metabolite intermediate levels were increased 167 
percent for gluconate, 250 percent for 6-phosphogluconate and 50 percent for ribose-5-phosphate by 
stimulation of glucose as pre-culture time extended. Similarly, glycerol 1-phosphate, another glucose 
cytosolic metabolite involved in the polyol pathway, was increased by 118 percent by stimulation of 
glucose as pre-culture time extended. Another similar product, glycerol-2-phosphate, was up-
regulated by 94 percent in the same condition. 
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Figure 5-5 Time-dependent effects revealed by TCA intermediates 
Metabolites are isolated from INS-1 832/13 beta cells, run on GC/MS and identified by 
searching spectra against Fiehn library. The metabolites levels are normalized by internal 
standards (Myristic acid D-27).  A) Citrate/Isocitrate, B) alpha-Ketoglutarate, C) Succinate, D) 
Fumurate, E) Malate. (LG = 2 mM glucose; HG = 10 mM glucose) (n=4). 1 hr LG versus 2hr or 
3hr LG #, p <0.05; ##, p <0.01; 1 hr HG versus 2hr or 3hr HG *, p <0.05; **, p <0.01 
0
10
20
30
40
50
60
70
LG HG LG HG LG HG
1hr 2hr 3hrR
el
a
ti
v
e 
M
et
a
b
o
li
te
 L
ev
el
(Iso)Citrate
0
10
20
30
40
50
60
70
80
90
LG HG LG HG LG HG
1hr 2hr 3hrR
el
a
ti
v
e 
M
et
a
b
o
li
te
 L
ev
el
a-Ketoglutarate
0
5
10
15
20
25
30
35
LG HG LG HG LG HG
1hr 2hr 3hrR
el
a
ti
v
e 
M
et
a
b
o
li
te
 L
ev
el
Succinate
0
2
4
6
8
10
12
14
LG HG LG HG LG HG
1hr 2hr 3hrR
el
a
ti
v
e 
M
et
a
b
o
li
te
 L
ev
el
Fumarate
0
10
20
30
40
50
60
70
80
90
100
LG HG LG HG LG HG
1hr 2hr 3hrR
el
a
ti
v
e 
M
et
a
b
o
li
te
 L
ev
el
Malate
C
B
D
E
***
* *
** **
#
#
#
#
#
#
#
#
#
#
#
#
**
  89 
 
Figure 5-6 Time-dependent effects revealed by pentose phosphate pathway intermediates 
Metabolites are isolated from INS-1 832/13 beta cells, run on GC/MS and identified by 
searching spectra against Fiehn library. The metabolites levels are normalized by internal 
standards (Myristic acid D-27). A) Gluconate, B) 6-phosphgluconate, C) Ribose-5-phosphate, D) 
beta-Glycerolphosphate, E) Glycerol-1-phosphate. (LG = 2 mM glucose; HG = 10 mM glucose) 
(n=4). 1 hr LG versus 2hr or 3hr LG #, p <0.05; ##, p <0.01; 1 hr HG versus 2hr or 3hr HG *, p 
<0.05; **, p <0.01 
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Alanine and hydroxy-proline both were negatively correlated with TDE, since metabolite levels 
decreased along pre-culture time by as much as 80 percent for alanine and 90 percent for hydroxyl-
proline under either non-stimulatory or stimulatory glucose conditions. Despite their different roles in 
regulation of GSIS, both serine and aspartate levels under stimulation of stimulatory glucose were 
increased along pre-culture time. 
 
Figure 5-7 Time-dependent effects revealed by amino acids 
Metabolites are isolated from INS-1 832/13 beta cells, run on GC/MS and identified by 
searching spectra against Fiehn library. The metabolites levels are normalized by internal 
standards (Myristic acid D-27). A) Alanine, B) Serine C) Hydroxy-proline, D) Aspartate.  (LG = 
2 mM glucose; HG = 10 mM glucose) (n=4). 1 hr LG versus 2hr or 3hr LG #, p <0.05; ##, p 
<0.01; 1 hr HG versus 2hr or 3hr HG *, p <0.05; **, p <0.01 
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5.4 Discussion 
Under physiological conditions, the pancreatic beta cell is never subjected to short-lasting 
stimulations. At any given time, the secretory activity of pancreatic beta cells is not only influenced 
by the present stimuli, but is also conditioned, either positively or negatively, by the memory of past 
stimuli. Therefore, the study of these regulatory mechanisms is imperative when determining the 
molecular basis of dynamic insulin secretion.  
As seen in Figure 1, when INS-1 832/13 cells were primed with 2 mM glucose for different periods of 
time, a TDI of insulin secretion was observed in cells treated with a non-stimulatory glucose, but not 
in cells treated with glucose at the stimulatory level. Cells appeared to secrete approximately the same 
amount of insulin, regardless of pre-culture conditions, which could be a result of either a deficiency 
of TDI or, alternatively, the neutralization of TDI by an opposing mechanism, e.g. TDP. In order to 
discriminate between these two possible mechanisms, insulin secreted within the first 10 min. of 
stimulatory glucose exposure was measured and exhibited a clear increasing pattern over pre-culture 
time. This observation suggests the existence of an opposing potentiation effect that neutralizes the 
TDI effect. Interestingly, this potentiation effect occurred at the same time as the peak observed in the 
first phase of insulin secretion. 
This potentiation effect elicited by stimulatory glucose was further supported by our metabolomics 
data shown in Figure 5-2F. In the absence of TDI, metabolic activity should remain relatively stable 
even with changing pre-culture conditions. However, as seen in Figure 5-2F, many metabolite levels 
were distinctly up-regulated as pre-stimulatory period prolongs. Hence, we conclude that TDI is 
present in cells treated with both basal and stimulatory glucose. However, in the latter case, an 
opposing mechanism also exists which neutralizes the TDI effect making it seemingly invisible. 
Therefore, distinct changes in the metabolome in response to glucose could be anticipated, enabling 
us to develop a metabolomic analysis of pancreatic beta cells to investigate the mechanism of TDE. 
Our OPLS model, as shown in Figure 5-3 not only supports the conclusion drawn from the above 
data, but also enables the discovery of potential coupling factors mediating TDE by effectively 
summarizing the data (98.7% information was reflected by new data). Among all the metabolites 
detected by our system, 19 well-studied metabolites were found to be strongly associated with the 
metabolic response of cells to either insulin secretion or TDE (Figure 5-3D).  
As the coefficient plot (Figure 5-3D) shows, two glycolytic intermediates, DHAP and 3-
phosphoglycerate，are identified as the most significant coupling factors involved in TDE, although 
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one is positively and the other is negatively correlated to TDE. DHAP, one of two products of 
generated by fructose 1,6-bisphosphate breakdown, is the only glycolytic metabolite that cannot be 
used directly and hence, needs to be converted to glyceraldehyde 3-phosphate (GADP) (the other 
produce generated by fructose 1,6-bisphosphate breakdown) for the further process in glycolysis. 
Therefore, the divergence brought in by DHAP provides a good opportunity for transmitting the 
message carried by glycolysis to other metabolic pathways. DHAP is also involved in a cytosolic 
glucose metabolism pathway, the polyol pathway, which is speculated to play a certain role in insulin 
secretion of primary human islets as our data shows (Figure 3-11). 
The steady-state quantity of each metabolite is the net balance between its production and 
consumption. Hence, the observed decrease in DHAP should result from either the relative decrease 
of its available upstream metabolites, e.g. fructose 1,6-bisphosphate, or the relative increase in 
production of its down-stream metabolites, e.g. GADP, and/or alpha-glycerolphosphate (alpha-GP). 
Neither fructose 1,6-bisphosphate nor GADP were detected by our system. However, three other 
affected compounds were identified. Glucose 6-phosphate (G6P), the upstream metabolites of 
fructose 1,6-bisphosphate, along with the downstream intermediates of DHAP and 3-
phosphoglycerate (3PG) and alpha-GP, were elevated in our study. 
Both alpha-GP and DHAP are essential intermediates for the glycerol phosphate shuttle. As our data 
shows, despite the elevated alpha-GP level, DHAP is markedly decreased by a longer pre-culture 
period, and could potentially lead to a decrease of cytosolic NAD
+
/NADH ratio. NADH re-oxidation 
is tightly regulated in pancreatic beta cells to maintain an optimal NAD
+
 level such that glycolysis 
remains unhindered [405, 406]; hence the postulated decrease of NAD
+
/NADH ratio will likely affect 
glycolysis. Similar to the decreased DHAP: alpha-GP ratio, malate and aspartate, two intermediates in 
the malate-aspartate shuttle, which is another cycle to regenerate NADH, were also reversely 
correlated to TDE and could cause a reduction of NAD
+
/NADH ratio. Additionally, the reduced 
lactate output observed in samples pre-treated for a longer time also fits nicely with the above 
observations. The extension of pre-stimulatory period decreased lactate output (Figure 5-4E). The 
generation of lactate is governed by lactate dehydrogenase (LDH), which remains highly active in 
insulinoma-derived beta cell lines [407, 408], and leads to the re-oxidation of NADH. Hence a 
preliminary conclusion can be drawn that cytosolic redox state, reflected by DHAP: alpha-GP ratio, 
malate-aspartate shuttle activity as well as lactate output, could mediate the TDI effect. 
The reduction in DHAP: alpha-GP ratio is related to the activity occurring in the glycerol phosphate 
shuttle. The oxidation of alpha-GP to DHAP can be achieved by two reactions: a NAD
+
-linked 
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cytosolic glycerol phosphate dehydrogenase and/or a mitochondrial FAD-linked glycerol phosphate 
dehydrogenase in the glycerol phosphate shuttle. Formation of DHAP from alpha-GP by the cytosolic 
glycerol phosphate dehydrogenase is an equilibrium reaction that should not alter the DHAP:alpha-
GP ratio [405]. On the contrary, oxidation of newly formed alpha-GP to DHAP by the FAD-linked 
glycerol phosphate dehydrogenase in the mitochondrial loop of the glycerol phosphate shuttle does 
affect the DHAP:alpha-GP ratio [405, 406, 409, 410]. Thus, the elevation of alpha-GP and the 
decrease of DHAP could result from the blocking or decrease of mitochondrial FAD-linked glycerol 
phosphate dehydrogenase activity, suggesting that glucose mitochondrial metabolism is involved in 
mediating TDP. 
Two potential coupling factors for TDE, 3-phosphoglycerate [97, 411] and citrate [97], were shown to 
couple glucose sensing to insulin exocytosis by specifically inactivating divalent-cation independent 
serine/threonine protein phosphatase (PPase) [97, 411, 412].  Complementary to the increased activity 
of protein kinases, PPase inhibition is believed to be an important mechanism also contributing to and 
further augmenting the event elicited by phosphorylation-stimulated pancreatic beta cell regulatory 
proteins [413] during stimulation of insulin exocytosis, including the hyper phosphorylation and 
hence activation of voltage-activated L-type Ca
2+
 channels [97, 98, 413-416]. Hence, the TDI effect 
was obscured in stimulatory glucose-treated beta cells probably by the activation of insulin exocytosis 
resulting from the elevation of 3-phosphoglycerate and citrate.  
However, this counteracting mechanism neutralizes but does not overcome the naturally elicited TDI 
effect on insulin secretion, likely because there is not enough insulin content and succinate-mediated 
proinsulin biosynthesis to sustain an observable potentiation effect. Although insulinoma cell line 
INS-1 retains many important characteristics of primary pancreatic beta cells and sustains the 
responsiveness to glucose within the physiological range, the total insulin content is only 20% of that 
of the native cells [417]. On the other hand, the regulation of insulin secretion and proinsulin 
biosynthesis have been shown to be tightly coupled, so that under normal circumstances intracellular 
insulin stores are replenished optimally and in a timely fashion for a proper insulin secretion upon 
demand [418-420]. This inconsistency can be explained by the action of succinate, which is an 
important coupling factor for glucose-stimulated proinsulin biosynthesis in rat pancreatic islets [421-
423]. Since succinate was affected by pre-stimulation, it might cause an uncoupling of insulin 
secretion and proinsulin synthesis, in addition to the depressed insulin content of INS-1 insulinoma 
cells, which might explain the difference of TDE between primary pancreatic beta cells and 
insulinoma cell line.  
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As our data suggest, the TCA cycle seems to be split into two mini-cycles based on their response to 
the pre-stimulatory period. With an increase in pre-culture duration, the first half cycle from citrate to 
alpha-ketoglutarate was up-regulated by stimulatory glucose and the second half from succinate to 
malate was down-regulated by non-stimulatory glucose as pre-stimulatory period persisted. This 
phenomenon agrees with the investigation done by Rustin and Yudkoff [424, 425], which suggests 
that the TCA cycle is comprised of two mini-cycles that are interconnected by the malate-aspartate 
shuttle [425], with one segment ranging between oxaloacetate and alpha-ketoglutarate, whereas the 
other segment extends from alpha-ketoglutarate to oxaloacetate [424]. This alternate 
conceptualization of the TCA cycle is supported by the observation that both segments can operate at 
different rates. As evidenced in rat brain synaptosomes, the metabolite flux between alpha-
ketoglutarate and oxaloacetate was estimated to be three to five fold higher than that between 
oxaloacetate and 2-oxoglutarate.  The branch of anaplerosis that enhances the supply and utilization 
of alpha-ketoglutarate in the TCA cycle also plays an essential role in the generation of TDP [403], 
but the mechanism and the down-stream pathways have yet to be elucidated. As seen in our 
unpublished data, there is evidence that it might be acting through alpha-ketoglutarate hydroxylases 
[95]. 
The role of the PPP in GSIS is still under investigation, since a number of studies in the last 30 years 
have produced some contradictory results [33, 77, 150, 346-348] . Based on our unpublished data in 
Figure 3-11D, the PPP and polypol pathway are speculated to affect TDE through a potentiating 
mechanism, which also contributes to the regulation of GSIS in human islets (Figure 3-11). This TDP 
provides a dynamic feedback mechanism and can adapt pancreatic beta cells to changes of 
environment, which is extremely useful for maintaining a good glucose homeostasis. The disruption 
of this feedback mechanism could lead to the partial functional loss of beta cells and eventually to 
development of type 2 diabetes. 
Additional amino acids, such as alanine, glycine, and serine, are known to induce a greater 
enhancement of both glucagon and insulin secretion than other amino acids [371], but their exact 
function in pancreatic beta cells remains elusive. Metabolomics is an important tool to study insulin 
secretion, because it is driven by glucose metabolism. However, as shown in our study, data mining 
and data interpretation of such a complex data set in a systematic way still highly relies on the 
researchers’ experience and knowledge.  
Aside from a few inherent drawbacks, such as derivatization, which might introduce bias into a 
metabolomics analysis, GC-MS is still considered to be one of the best metabolite detection and 
  95 
measurement technologies due to its good sensitivity, high resolution, decent reproducibility and nice 
robustness. As our study showed, untargeted metabolomics coupled with powerful chemometric 
analysis provides a comprehensive data set, which, when contextualized with proper and abundant 
knowledge of metabolic pathways and/or signaling networks, can fuel a truly mechanistic 
biochemical study, and can even lead to an unanticipated discovery complementary to the original 
topic investigated. However, as the core of a robust mechanistic study, proper verification and more 
strict validation are required to assist the interpretation of metabolomics data, since the cause-effect 
relationships cannot be revealed by metabolomics.  
5.5 Conclusion 
It is concluded that TDE does exist in the INS-1 832/13 cell line, and pre-culturing cells in non-
stimulatory glucose does affect acute stimulation-secretion coupling in the following way: the longer 
the pre-culture time, the higher the acute insulin response. In fact, the acute stimulation on insulin 
secretion, which can be easily modified by pre-culture, likely constitutes the first phase of biphasic 
insulin secretion. However, regardless of the pre-culture condition, the same amount of insulin 
secretion was elicited by stimulatory glucose as a result of the net balance between the concurrent 
acute stimulation, as well as TDI and TDP for applied-stimuli lasting longer than threshold duration. 
As our metabolomics data suggested, TDI effect may be regulated by the redox state of pancreatic 
beta cells, reflected by DHAP: alpha-GP ratio, the diminished malate-aspartate shuttle activity, the 
lowered lactate output and the altered NAD
+
/NADH ratio.  Alternatively, TDP is mainly correlated to 
phosphorylation-mediated insulin exocytosis, which is, probably coupled to succinate-regulated pro-
insulin biosynthesis. Because TDI is directly mediated by glucose metabolism and TDP is likely 
correlated with the proximal part of the stimulus-response coupling pathway, e.g. glucose-stimulated 
insulin exocytosis as well as pro-insulin biosynthesis, TDI is generated sooner than TDP as reported. 
In summary, our study unravels important metabolic pathways involving glycolysis and anaplerosis 
that differentially modulate TDI and TDP in response to previously applied glucose and hence 
constitute biphasic insulin secretion. Furthermore, our study proves the tremendous promise offered 
by the application of metabolomics in the mechanistic study of biochemical research. 
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Chapter 6 
Hydroxylation, an Important Mechanism in Regulation of 
Glucose Metabolism 
6.1 Overview 
The metabolic pathways involved in regulating glucose stimulated insulin secretion (GSIS) remain 
incompletely understood. Previous studies have pointed to glucose derived anaplerotic and 
cataplerotic signals as part of the regulation mechanism. Of all possibilities, alpha-ketoglutarate and 
its relevant effectors have received the most attention. Our study demonstrates that inhibition of 
alpha-ketoglutarate dependent hydroxylation resulting from iron deficiency created by ethyl-3,4-
dihydroxybenzoate (EDHB) has a dose-dependent effect on GSIS in both INS-1 cell lines and 
primary rat islets.  Low dosage EDHB can promote a moderate increase of insulin secretion by 
enhancing beta cell oxygen consumption used for ATP generation without altering glycotic influx. 
However, a high level of EDHB severely impairs pancreatic beta cell secretion competency by 
attenuating both cytoplasmic and mitochondrial glucose metabolism, as seen through a reduction of 
both glycolytic and anaplerotic metabolites. The fact that neither the expression nor the function of 
hypoxia-inducible factor-1alpha (HIF-1alpha) is altered indicates that short-term inhibition of 
hydroxylation can work through a HIF-1alpha independent mechanism. Based on these data, our 
study suggests iron-dependent hydroxylation is important for both cytoplasmic and mitochondrial 
glucose metabolism and may play a critical role in regulation of pancreatic beta cell secretion 
function. 
6.2 Introduction 
Despite decades of efforts, only one well-established glucose metabolism and insulin secretion 
coupling pathway is widely accepted by scientists studying insulin secretion. This pathway is initiated 
by an increase in the ATP/ADP ratio leading to inhibition of ATP-sensitive K
+
 (KATP) channels, 
plasma membrane depolarization, activation of voltage-gated Ca
2+
 channels, and eventually influx of 
extracellular Ca
2+
 serving to activate insulin granule exocytosis [48, 50, 65, 426]. This pathway is 
hence referred to as the KATP channel dependent pathway or triggering pathway. However, other 
studies revealed that islets were still able to retain their insulin secretion function in conditions 
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lacking functional KATP channels [60-62, 64] or when KATP channels were held open [56, 57].  
Accordingly, this unknown coupling mechanism between glucose metabolism and insulin secretion 
was called the KATP channel independent pathway or amplifying pathway [109]. This pathway has 
been suggested, by accumulating evidence, to potentially involve the activity of several other 
coupling factor(s) that link mitochondrial metabolism to insulin secretion, such as GTP [331, 427], 
glutamate [94, 339, 428, 429], malonylCoA/LC-CoA [336, 337, 430], NADPH [338, 431, 432] and 
pyruvate carboxylase (PC) -mediated anaplerosis [49, 76, 81, 84, 353, 433, 434]. 
The correlation between GSIS and pyruvate cycling has led to active investigations of glucose-
derived anaplerosis and cataplerosis to elucidate the mechanism of KATP channel independent 
pathway in regulation of fuel-induced insulin secretion [76, 80-82, 84]. Of particular interest are the 
coupling factors generated by the pyruvate-isocitrate cycling pathway. In this pathway, both citrate 
and isocitrate leave mitochondria through the citrate-isocitrate carrier (CIC), and enter the cytoplasm 
where they are converted into alpha-ketoglutarate by a cytosolic NADP-dependent isocitrate 
dehydrogenase (ICDc) (citrate is first converted into isocitrate by cytosolic aconitase before ICDc can 
act on it). Alpha-ketoglutarate can flux back into TCA cycle in the mitochondria via 2-oxoglutarate 
carrier (OGC). The importance of this pathway has been underlined by studies showing that 
suppression of CIC, ICDc and OGC strikingly impaired GSIS [81, 82, 84].   
In addition to its involvement in pyruvate-isocitrate cycling, alpha-ketuglutarate has been implicated 
in insulin secretion by two other recent studies. First, alpha-ketoglutarate itself can act as an insulin 
secretagogue [435]. Second, alpha-ketoglutarate-dependent hydroxylases have been shown to 
participate in GSIS, either directly or indirectly [95, 96]. The Fe(II)/alpha-ketoglutarate-dependent 
hydroxylase superfamily serves to catalyze a variety of reactions, in which decarboxylation of alpha-
ketoglutarate produces succinate and CO2 and an active oxygen species leading to the hydroxylation 
of the primary substrate [390]. Inhibitors of alpha-ketoglutarate-dependent hydroxylases promptly 
decrease insulin secretion in rat pancreatic islets [95]. In the long term, increase of hypoxia-inducible 
factor-1alpha (HIF-1alpha) levels by deferoxamine (DFO) or deferasirox (DFS), which stops HIF-
1alpha hydroxylation via iron chelation, enhances insulin secretion and beta cell function in mice 
[96]. These studies suggest that Fe(II)/alpha-ketoglutarate-dependent hydroxylases might be 
important effectors in defining the extramitochondrial role of alpha-ketoglutarate in insulin secretion. 
To explore the role of Fe(II)/alpha-ketoglutarate-dependent hydroxylases in regulation of insulin 
secretion, ethyl-3,4-dihydroxybenzoate (EDHB), a cell-permeable inhibitor that competitively binds 
to prolyl hydroxylases (PHDs) which initiates ubiquitination and proteolysis of HIF-1alpha by 
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hydroxylating the proline residue,  was used to impair iron-dependent hydroxylation in pancreatic 
beta cells.  Our study of the effect of EDHB on beta cell stimulus secretion provides convincing 
evidence that iron-dependent hydroxylation plays an important role in regulation of insulin secretion 
through a HIF-1alpha independent mechanism. 
6.3 Results 
6.3.1 EDHB affects insulin secretion in INS-1 832/13 cells 
An insulin secretion assay was performed first on INS-1 832/13 cells to test the effect of EDHB on 
pancreatic beta cells. As Figure 6-1A shows, 0.2 mM EDHB markedly improved insulin secretion by 
58 percent and 0.5 mM EDHB also had a similar effect on INS-1 832/13 cells treated with 
stimulatory glucose concentrations (10 mM glucose). However, high dosage EDHB (1mM) 
significantly decreased insulin release in static incubation studies by 70 ± 4% as compared to control 
cells (Figure 6-1B), without affecting cell viability. In fact, total cellular protein levels were increased 
25 ± 5% by 0.5 mM EDHB and 60 ± 8% by 1 mM EDHB as shown in Figure 6-1C.  
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Figure 6-1 Effects of EDHB on insulin secretion and cell viability 
Different dosage of EDHB was used to treat either cells or islets and then (A) insulin secretion, 
(B) cell viability and (C) total protein level in INS-1 832/13 cells, and insulin secretion on (D) rat 
islets (E) human islets were measured. Results represent mean ± S.E. (n = 6-12 replicates 
incubations for each condition). LG, low glucose (2 mM); HG, high glucose (10 mM). Non-
treated versus treated group, * p < 0.05; ** p < 0.01 versus same secretagogue condition without 
ethyl-3,4-dihydroxybenzoate (EDHB) for insulin secretion. 
6.3.2 EDHB affects insulin secretion in primary rat and human islets 
The effect of EDHB on insulin secretion was further investigated by running an insulin secretion 
assay on primary islets. Although the low dosage amounts differed from that used in INS-1 832/13 
cells, the same dose-dependent reverse effect was observed on freshly isolated rat islets as shown in 
Figure 6-1D, in which cells treated with 0.05 mM EDHB were able to secret 30 percent more insulin 
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than untreated cells. Treatment with the intermediate dose of 0.1 mM EDHB seemed to have a slight 
effect on enhancing insulin secretion, but was not significant. However, high dosages of EDHB, 
represented by 0.5 mM and 1 mM, impaired insulin release in rat islets (Figure 6-1D) to almost the 
same extent (by 70 ± 8%) as that observed in INS-1 832/13 cells (Figure 6-1C). The  insulin secretion 
deficiency elicited by high dosage of EDHB was even more noticeable in human islets (Figure 6-1E) 
compared to rat islets. The loss of insulin secretion at stimulatory glucose level was as high as 79.97 
± 8.1 percent. Similarly, a small amount of EDHB did not seem to alter secretion function in human 
islet. 
6.3.3 EDHB affects glucose utilization and oxygen consumption 
Glucose metabolism is tightly coupled to insulin secretion in pancreatic beta cells. Glucose utilization 
and oxygen consumption are two factors indicating the overall glucose metabolism as well as the 
activity of pancreatic beta cells. Hence, both glucose utilization and oxygen consumption were 
assessed to evaluate the effect of EDHB on glucose metabolism. As expected, stimulatory glucose (10 
mM) induced a 6 fold increase (±0.35) in glycolytic flux and 1.8 fold increase (±0.04) in oxygen 
consumption from both untreated and control (treated with the same amount of ethanol used to 
dissolve EDHB) INS-1 832/13 cells (Figure 6-2A). 1mM EDHB treatment resulted in 40 ± 5% 
decline of glycolytic flux (Figure 2A), but had no obvious effect on oxygen consumption (Figure 6-
2B).  On the contrary, 0.2 mM EDHB caused 1.7 fold increase (±0.18) in oxygen consumption 
(Figure 6-2B), but did not affect glycolytic flux (Figure 6-2A). Further analysis showed that the 
oxygen consumption specifically needed for ATP generation (Figure 6-2C) was raised by the same 
ratio as the overall oxygen consumption in 0.2 mM EDHB treated cells. On the other hand, cells 
treated with 1 mM EDHB used 60 ± 5% less oxygen for ATP generation, also seen in Figure 6-2C.  
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Figure 6-2 Effects of EDHB on glucose metabolism 
Different dosage of EDHB was used to treat either cells or islets and then (A) glucose utilization 
and (B) oxygen consumption and (C) oxygen consumed for ATP generation in INS-1 832/13 
cells were measured. Results represent mean ± S.E. (n = 8~18 replicates incubations for each 
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condition). LG, low glucose (2 mM); HG, high glucose (10 mM). * p < 0.05; ** p < 0.01 versus 
same secretagogue condition without ethyl-3,4-dihydroxybenzoate (EDHB). 
6.3.4 EDHB has no effects on HIF-1alpha expression or function 
EDHB is a cell-permeable inhibitor that competitively binds to prolyl hydroxylases (PHDs), which 
initiates ubiquitination and proteolysis of HIF-1alpha by hydroxylating proline residue. Therefore, 
HIF-1alpha expression and transcriptional function were tested to investigate whether the effect of 
EDHB on insulin secretion is through the HIF-1alpha dependent mechanism. 
As shown in Figure 6-3, both endogenous HIF-1alpha mRNA (Figure 6-3A) and protein (Figure 6-3B 
and 6-3C) level in INS-1 832/13 cells remained unchanged after one hour EDHB treatment. A real-
time PCR assay revealed that mRNA levels of HIF-1alpha targeting genes (Figure 6-4), including aryl 
hydrocarbon receptor nuclear translocator (ARNT), glucose transporter 2 (Glut2), glucokinase (GK), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), pyruvate kinase muscle isozyme 1 (PKM1), 
pyruvate kinase muscle isozyme 2 (PKM2), also remained unaffected even if cellular hydroxylation 
was inhibited by EDHB. 
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Figure 6-3 Effects of EDHB on hypoxia-inducible factor 1-alpha (HIF-1alpha) gene and protein  
(A) RT-PCR analysis of HIF-1alpha mRNA (B) Immunoblot analysis of HIF-1alpha and γ-
tubulin protein (C) HIF-1alpha protein level normalized by γ-tubulin. Results represent mean ± 
S.E. (n = 4-9 replicates incubations for each condition. INS-1 832/13 cells were incubated with 
2mM glucose for 2 hr and then treated with different levels of glucose as indicated for 1 hr 
before harvested for further analysis. 
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Figure 6-4 Effects of EDHB on HIF-1alpha target genes 
(a) Aryl hydrocarbon receptor nuclear translocator (ARNT) (b) glucose transporter 2 (Glut2) 
(c) glucokinase (GK) (d) glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (e) pyruvate 
kinase muscle isozyme 1 (PKM1) (f) pyruvate kinase muscle isozyme (PKM2) mRNA 
expression in INS-1 832/13 cells.  Results represent mean ± S.E. (n = 6-8 replicates incubations 
for each condition). 
6.3.5 Prolyl hydroxylases suppression has no effect on GSIS 
For each prolyl hydroxylase (PHD1, 2 and 3), two siRNA duplexes targeting different gene regions 
were transfected into INS-1 832/13 cells. A previously characterized, a nonspecific siRNA sequence 
(siControl) was used as the control [81, 84, 319]. As shown in Figure 6-5, an 80 percent decline of 
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mRNA for each PHD was obtained by using both siRNA treatments; however, inhibiting individual 
PHD did not cause any significant effect on insulin release.  
 
Figure 6-5 Effects of siRNA-mediated suppression of prolyl hydroxylases GSIS  
Effects of two siRNA duplexes (siPHD1-1 and siPHD1-2) targeting against PHD1 on (a) GSIS 
and (b) PHD1 expression. Effects of two siRNA duplexes (siPHD2-1 and siPHD2-2) targeting 
against PHD2 on (c) GSIS and (d) PHD2 expression. Effects of two siRNA duplexes (siPHD3-1 
and siPHD3-2) targeting against PHD3 on (e) GSIS and (f) PHD3 expression. siRNA duplexes 
were introduced into 832/13 cells at ~50% confluence. Experiments were performed 72 h after 
transfection. mRNA values are normalized to cyclophilin. Results represent mean ± S.E. (n = 9-
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12 replicate incubations for each condition). LG, low glucose (2 mM); HG, high glucose (10 
mM). * p < 0.05 ; ** p < 0.01 versus same secretagogue condition without siRNA duplex. 
6.3.6 High dosage of EDHB affects glucose metabolism 
To further investigate the mechanism of EDHB in regulation of pancreatic beta cell secretion 
function, a GC-MS metabolomics approach was used to study the metabolite profiling of glycolytic 
and anaplerotic responses. As shown in Figure 6-6, the glycolytic intermediates, glucose 6-phosphate, 
3-phosphoglycerate and pyruvate, were down-regulated by at least 75 percent after one hour 
treatment of 1 mM EDHB, but remained unaltered by 0.2 mM EDHB. Lactate remained unchanged in 
any of these conditions.  
 
 
Figure 6-6 Effects of EDHB on glycolysis metabolites  
Metabolites are isolated from INS-1 832/13 beta cells, run on GC/MS and identified by 
searching spectra against Fiehn library. The metabolites levels are normalized by internal 
standards (Myristic acid D-27). (A) Glucose 6-phosphate  (B) 3-Phosphoglycerate (C) Pyruvate 
(D) Lactic Acid in INS-1 832/13 cells. Represent mean ± S.E. (n = 6 replicates incubations for 
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each condition). LG, low glucose (2 mM); HG, high glucose (10 mM). **, p<0.01, non-treated 
versus EDHB treated 
All glucose-derived anaplerotic metabolites, which were detected by our mass spectrometer, exhibited 
the same trend as glycolytic intermediates (Figure 6-7). The levels of TCA cycle metabolites 
remained unchanged in cells treated with 0.2 mM EDHB, but were inhibited to the same extent as 
glycolytic intermediates in cells treated with 1 mM EDHB.  
 
Figure 6-7 Effects of EDHB on TCA metabolites  
Metabolites are isolated from INS-1 832/13 beta cells, run on GC/MS and identified by 
searching spectra against Fiehn library. The metabolites levels are normalized by internal 
standards (Myristic acid D-27). (A) Citrate  (B) alpha-Ketoglutarate (C) Succinate (D) 
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Fumurate (E) Malate in INS-1 832/13 cells. Represent mean ± S.E. (n = 6 replicates incubations 
for each condition). LG, low glucose (2 mM); HG, high glucose (10 mM). **, p<0.01, non-
treated versus EDHB treated 
Aspartate, which has been shown repeatedly by our previous studies to be negatively correlated to 
GSIS [320], was markedly impaired by 1 mM EDHB treatment (Figure 6-8).  
  
Figure 6-8 Effects of EDHB on aspartate 
Metabolites are isolated from INS-1 832/13 beta cells, run on GC/MS and identified by 
searching spectra against Fiehn library. The metabolites levels are normalized by internal 
standards (Myristic acid D-27). Represent mean ± S.E. (n = 6 replicates incubations for each 
condition). LG, low glucose (2 mM); HG, high glucose (10 mM). **, p<0.01, non-treated versus 
EDHB treated 
 
6.4 Discussion 
Insulin secretagogue carbon derived anaplerosis has been shown to play an important role in 
maintaining the secretion function of pancreatic beta cells. Theoretically, cataplerosis should be 
equally important as anaplerosis because glucose derived carbon fed into the TCA cycle through PC 
needs to find a way to leave mitochondria. One of the main reasons for the metabolite translocation 
from mitochondria to cytoplasm is to enable the signal generated in the mitochondrion, where glucose 
derived carbon fluxes into primary metabolism, to travel to the cytoplasm, where insulin granule 
exocytosis actually happens. Previous studies have brought our attention to alpha-ketoglutarate and its 
cofactors, among which Fe(II)/alpha-ketoglutarate dependent hydroxylases are believed to be 
promising candidates.  
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Fe(II)/alpha-ketoglutarate-dependent hydroxylase is a superfamily of enzymes consisting of more 
than 30 members identified from different species [390]. All members in this whole enzymes family 
are characterized by their ability to selectively catalyze the decomposition of alpha-ketoglutarate 
along with the formation of CO2, succinate and an active oxygen species [390, 436]. Both its substrate 
(alpha-ketoglutarate) and product (succinate), are active members of the TCA cycle, therefore, the 
Fe(II)/alpha-ketoglutarate-dependent hydroxylase has received lots of attention as a highly 
competitive potential factor coupling glucose metabolite with insulin secretion. 
In order to investigate the involvement of Fe(II)/alpha-ketoglutarate-dependent hydroxylase in GSIS,  
EDHB was used to create an iron-deficient condition inside pancreatic beta cells, because EDHB is 
capable of chelating the enzyme-bound iron [437] and effectively inhibiting the activity of enzymes. 
As shown in Figure 6-1, a high dosage of EDHB represented by 1mM in INS-1 cells and over 0.5 
mM in rat and human pancreatic islets can significantly lower insulin release without causing any cell 
toxicity in a short term, a finding which is consistent with previous studies [95].  Surprisingly, insulin 
released by cells treated with small amounts of EDHB (0.2 mM in INS-1 832/13 cells and 0.05 mM 
in islets) was actually improved. This enhancement is most likely due to the stimulation of an energy 
relevant process rather than glucose uptake, since glucose influx did not change but oxygen 
consumption rose substantially. The incremental increase of total oxygen consumption was almost the 
same as that used for ATP generation, which suggests that hydroxylation might be involved in 
maintaining ATP generation. Although no gross change in total oxygen consumption occurred as a 
consequence of 1 mM EDHB treatment, both glucose utilization and ATP generation were impaired, 
indicating that some oxygen-dependent cellular activities increased in order to make up for the loss of 
oxygen consumption used for ATP generation.  
EDHB was commonly used as a cell-permeable inhibitor for prolyl hydroxylases [438, 439]. 
Endogenous PHDs [440-442], one of the first Fe(II)/alpha-ketoglutarate-dependent hydroxylases 
identified by Hutton [441], as well as lysyl hydroxylases [440, 443-446], have been detected in INS-1 
cells, rat and human pancreatic islets [95].  Prolyl hydroxylases can initiate HIF-1alpha ubiquitination 
and proteolysis by hydroxylation of HIF-1alpha on its proline residue [447-449]. Knowing this 
information, a further test was done to investigate whether the effect of EDHB on insulin secretion 
was through a HIF-1alpha dependent mechanism. Detection of HIF-1alpha expression revealed that 
neither its mRNA nor its protein level was affected by EDHB, although the total protein level was 
significantly altered by EDHB (Figure 6-1C). Additionally, HIF-1alpha’s ability to function as a 
transcription cofactor remains unaffected, since the expression of its targeting genes was not altered 
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as shown in Figure 6-4. This suggests EDHB regulates pancreatic beta cell function through a HIF-
1alpha independent mechanism, which might be relevant to hydroxylation-mediated ubiquitination 
and degradation, because the total protein level rose, indicating protein degradation was inhibited.  
Surprisingly, siRNA mediated inhibition of individual prolyl hydroxylase did not affect GSIS either, 
likely due to a compensation by other prolyl hydroxylase or even other groups of iron-responsive 
hydroxylases.  The discrepancy in insulin release between EDHB-induced iron deficiency and 
siRNA-mediated prolyl hydroxylase inhibition along with the dose-dependent reverse effects of 
EDHB strongly implies the existence of a regulatory network of iron-dependent proteins, which 
involves, but is not limited to just prolyl hydroxylases, in pancreatic beta cells. Further work needs to 
be done to identify the exact target(s) of prolyl hydroxylase and/or other iron-dependent components 
responsive to EDHB in this whole iron-regulatory protein network.  
This independency of HIF-1alpha mechanism is not only consistent with previous studies [450], but 
also supported by our metabolomics analysis. As shown in Figure 6-8, all glycolytic and TCA 
metabolites were down-regulated by 1 mM EDHB in INS-1 cells, which can explain why GSIS was 
extensively reduced in both INS-1 832/13 cells and islets. Metabolomics data also strongly indicates 
that hydroxylation is an important mechanism to globally control the glucose and TCA cycle 
metabolism, which will further exert their effects on insulin secretion.  
6.5 Conclusion 
In this study, EDHB was used to create an iron-free condition to study the role of alpha-ketoglutarate 
dependent hydroxylation in regulation of GSIS. It was found that EDHB had a dose-dependent effect 
on GSIS in both INS-1 cell lines and primary rat islets. Low dosage EDHB caused a moderate 
increase of insulin secretion probably by enhancing beta cell oxygen consumption used for ATP 
generation without altering glycotic influx. A high level of EDHB severely impaired pancreatic beta 
cell secretion function and reduced both glycolytic and anaplerotic metabolites. Neither the 
expression nor the function of hypoxia-inducible factor-1alpha (HIF-1alpha) was altered, which 
indicates that hydroxylation works through a HIF-1alpha independent mechanism. Overall, our study 
has revealed that iron-responsive and alpha-ketoglutarate dependent hydroxylation is an important 
mechanism to regulate glucose metabolism and that its existence is critical to the normal function of 
pancreatic beta cells. These data suggest that the existence of iron-responsive and alpha-ketoglutarate 
dependent hydroxylation in regulation of glucose metabolism actually provides a positive feedback 
loop for GSIS and offers a potential for diabetes treatment.  
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Chapter 7 
Discussion and Conclusion 
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7.1 Discussion 
7.1.1 Technique aspects of untargeted metabolomics 
In the postgenomic era, metabolomics has gained growing attention because it is capable of providing 
the most integrated profile of biological status. For example, the search for biomarkers, which serve 
as clear and strong indicators of disease progression, benefits from the progress of metabolomics. 
However, even with today’s powerful analytical instruments and computer technology, the 
unambiguous and simultaneous determination of the whole set of metabolome in a biological system 
currently remains a great challenge. The technique bottleneck is the lack of an efficient sample 
preparation method for unbiased metabolite extraction due to the chemical complexity of native 
metabolites and wide range of metabolites concentration (over three magnitudes). Therefore, an 
unbiased metabolite extraction process needs to be included in metabolomics sampling approaches, 
from tissue isolation and homogenization to metabolites extraction and storage. Sample preparation is 
also considered the limiting step in metabolome analysis because it is an important source of 
variability in the analysis. 
Our studies identified approximately 300 putative metabolites and their derivatives, which cover more 
than 20 chemical classes (data not shown), for example, amino acids, nucleotides, nucleosides, 
carboxylic acids, ketones, glycolipids, fatty acids, and sugar. This suggests that our extraction method 
works well. In fact, the combination of water and methanol is less comprehensive than the mixture of 
cold methanol/chloroform/water in terms of the coverage of metabolites polarity [194, 195, 197-201]. 
The latter was not used in our study because it was shown to affect the extraction of nucleotides, e.g 
ATP, ADP, NADP, NADPH, which play a vital role in coupling glucose metabolism to insulin 
secretion. In this case, the comprehensiveness of extraction methods was sacrificed for the efficiency 
and effectiveness of nucleotides extraction. Although carboxylic acids themselves are not compatible 
with GC-MS, they were constantly and repeatedly detected in our study with little variation, which 
suggests that they are structurally more amenable to chemical derivatization than nucleotides. 
In fact, only those volatile and less polar metabolites, which do not ionize very well by LC-MS 
ionization techniques, such as plant terpenes, steroids, diglycerides, mono-, di- and tri-saccharides, 
and sugar alcohols, are suited to GC-MS. In contrast, LC is commonly used to analyze those polar 
and not volatile metabolites, such as amino acids, organic acids, nucleosides, nucleotides, which 
actually covers a much wider range of chemical species. However, there is no publicly available 
MS/MS spectral library for LC-MS, like NIST for GC-MS. So the practical way to identify 
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metabolites based on LC-MS spectra is manual de novo interpretation and structure elucidation 
supported by MS/MS fragmentation from a high resolution mass spectrometer. Another advantage of 
GC over LC is the high chromatographic resolution, a benefit of long GC column (30 m GC column 
length vs. 0.15m LC column length), which allows a good separation of structurally similar 
metabolites, such as fatty acids. The last reason that GC is still a popular technique for metabolomics 
is that electron ionization (EI), the ionization commonly used in GC-MS, is robust and reproducible 
in producing MS spectra. 
It is worth mentioning that metabolomics can only measure steady-state metabolite levels and is not 
able to determine the turnover rate of metabolites, which can be obtained by metabolic flux 
measurement. Some metabolites might be at high level with a low turnover rate and other metabolites 
turn out to be at low level but actually with high turnover rate. In practice, metabolic flux can be 
determined by the time-dependent measurement of steady-state distribution of isotope labelled atoms 
presented in growth culture media, such as 
13
C, by NMR or MS [244]. This method is called 
‘metabolic balancing’.  
In some cases, although the overall concentration of metabolites is not altered by treatments, the 
change of relative metabolites abundance between different subcellular compartments, such as 
cytosol versus mitochondria, can provide further information and be used to reveal important 
mechanisms. To obtain such data, separation of different subcellular compartments prior to extraction 
of metabolites is necessary. 
Overall, the sample preparation method used in our studies, including quenching and metabolites 
extraction, was proved to be effective, providing satisfactory comprehensiveness, reproducibility and 
variation. 
7.1.2 Multivariate analysis in metabolomics 
Metabolomic data acquisition techniques generate a large volume of data containing hundreds or even 
thousands of observations and variables, which are rich in information. Therefore, MVA is an 
essential chemometrical tool integrated into untargeted metabolomics to reveal this underlying 
information.  
PCA has been recommended as the starting point for studies requiring MVA, because it provides a 
quick overview of data. Despite the many options we have, PCA is so far still the method widely used 
in metabolomics, and to date, majority of metabolomics publications are based on PCA. Only a few 
papers have tried PLS [451] or OPLS [148], even though this situation has changed in last couple of 
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years. As mentioned before, PCA cannot perform quantitative analysis and hence is not the right tool 
for biomarker discovery, for which purpose PLS or OPLS is recommended and expected to be 
developed to a major multivariate approach for untargeted metabolomics in the near future.  The 
combination of several MVA methods, such as hierarchical PCA and PLS, has been tested and proved 
to enhance data interpretation [289, 452-456].  
Both PLS and OPLS were tried in our study. As shown in chapter 3 to 6, OPLS was applied to two 
classes (Chapter 3) as well as dynamic studies (Chapter 4) in this thesis. Actually, OPLS was found to 
outweigh PLS in modeling, such as samples classification, data interpretation, and discovery of 
biomarkers. For example, PLS identified six new latent variables, while OPLS generated only three 
predictive and two orthogonal latent variables for an equally good modeling of metabolomics data 
designed to reveal the mechanism of TDEs in Chapter 5 (data not shown). This is mainly because 
orthogonal latent variables negatively affect PLS modeling and data interpretation, since they are just 
structure noise unrelated to Y matrix. 
No matter which MVA tool is used for data analysis, we found that large datasets were more effective 
in building more reliable and interpretable models than datasets with a low number of replicates. 
However, although an appropriate MVA method is powerful enough to find the underlying 
correlation obscured in the original data matrix, it cannot determine the cause-and-effect relationship 
between two phenomena. For example, although the PPP was shown by MVA to contribute to the 
cluster of high glucose treated cells in Chapter 3, we don’t know whether it is the elevated pentose-
phosphate pathway that promotes GSIS or it is extra glucose that fluxes into the PPP and hence 
increases the metabolites levels. So, what is even more important is rigorous verification or validation 
of results from MVA on both a statistical (Q2) and biological level. As seen in Figure 3-11, both 
siRNA mediated knockdown and pharmaceutical inhibitors of the PPP were used to verify the 
discovery by MVA and to test the cause-and-effect relationship between the PPP and GSIS. 
MVA is a chemometrical technique critical to reliable interpretation of metabolomics data. But it is of 
great importance to choose the appropriate method, to optimize different parameters and to apply 
strict validation as well as biologically meaningful verification. 
7.1.3 Significance of untargeted metabolomics 
The traditional strategy for research is generally hypothesis-driven, in which some preliminary 
knowledge is generally required for a formation of preconceived notions and their confirmation by 
some experiments designed to test the hypothesis [457, 458]. Preliminary knowledge and great 
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wisdom generated from experience play a considerable role in determining how valid the hypothesis 
is, since even data collected from well-designed experiments can agree with, be completely irrelevant 
to, or even contradict proposed hypothesis. That’s why the traditional knowledge discovery strategy is 
highly risky in terms of successful confirmation of a hypothesis and low throughput.  
In the post genomic era, some research intended to generate new knowledge has turned from a 
hypothesis-driven to data-driven stage, since scientists are capable of collecting a high amount of data 
simultaneously and the hypothesis or even knowledge is manifested by these observations themselves 
[459]. The novel knowledge discovery strategy benefiting from untargeted metabolomics doesn’t 
require preliminary data for proposal of hypothesis, and hence is especially useful for a novel project 
with little a priori background. This is why untargeted metabolomics is becoming more and more 
interesting to scientists.  
This data-driven strategy is clearly shown in Chapter 3-6. For example, in Chapter 5, if there is no 
untargeted metabolomics, a conclusion can be easily drawn that pre-culture condition has no effect on 
GSIS. However, a great discrepancy between insulin secretion competency (Figure 5-1A) and 
metabolic activity (Figure 5-2) was clearly revealed by untargeted metabolomics analysis, which gave 
a further clue about which metabolites are most likely responsible for TDE.  In Chapter 6, the 
untargeted metabolomics data once again links the HIF-1alpha independent mechanism to global 
regulation of glucose metabolism, thus providing a direction for further study (e.g. to investigate the 
hydroxylation status of enzymes involved in glycolysis and TCA cycle metabolism). 
7.1.4 Insight into metabolic regulation of insulin secretion 
Insulin secretion is tightly controlled by glucose metabolism. Hence, metabolite measurement is of 
particular importance in studies of the pancreatic beta cell secretion function. Metabolomic analysis 
has a distinct advantage over other classical biochemical approaches used for metabolite 
measurement, because metabolomics can directly determine the steady-state metabolite levels. 
Whether the PPP is involved in glucose stimulus and insulin secretion coupling in pancreatic cells 
function has been under debate. One reason to cause this argument is probably the difference between 
species. The major evidence against the idea that PPP participates in GSIS is from INS-1 cells and 
mouse islets [33, 354]. Studies showing the involvement of PPP in GSIS were done on human islets 
[149]. Our data (Figure 3-7 and 3-11) also indicates that a species difference exists between human 
and rat islets as reported [149]. The different culture conditions are the second reason for the 
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contradictory results revealed by studies investigating the role of PPP in regulation of pancreatic 
secretion function. Experiments generating the data denying the involvement of PPP in GSIS 
involved static incubation, in which insulin was secreted into and stayed in medium [33, 354]. 
However, insulin accumulation was reported to block and obscure glucose concentration-dependent 
PPP activity [348], if insulin was not removed from medium. In addition, the pre-culture condition 
affected the activity of PPP in rat islets [77]. Our data not only reveal the possibility that PPP might 
be a part of the regulatory network of pancreatic beta cells secretion function (Figure 3-11), but also 
indicate that the PPP might be specifically active in the first phase of insulin secretion (Figure 4-5A), 
which agrees with other studies done by Spégel [148]. The mechanistic study has mainly focused on 
the role of PPP in providing NADPH for defense against oxidative stress induced in pancreatic beta 
cells [349]. Much less attention has been paid to investigate whether the ability of PPP to generate the 
precursor for pentose synthesis of aromatic amino acids, and nucleotides is dispensable to GSIS, 
which remains established. 
TDEs were suggested to be one model to explain biphasic property of insulin secretion, because a 
tight correlation was discovered between the magnitude of TDP and the slope of the second phase 
insulin response [144]. However, our metabolomic analysis suggests that TDP is likely correlated 
with the proximal part of the stimulus-response coupling pathway, e.g. glucose-stimulated insulin 
exocytosis as well as pro-insulin biosynthesis (Chapter 5), while the alpha-ketoglutarate mediated 
proline hydroxylation might be central for the second phase insulin secretion (Chapter 4). Although 
both TDP and the second phase insulin secretion are driven by glucose-derived anaplerosis, the fact 
that they are governed by distinct mechanism indicates that TDP and the second phase of insulin 
secretion are two different characterizations of pancreatic beta-cells. Studies, which revealed that 
TDP can be induced by glucose in the absence of extracellular Ca
2+
 [460, 461] and was critically 
dependent on intracellular pH [460], also support our discovery that different mechanisms are 
responsible for TDP and the second phase insulin secretion. 
Our data suggests that metabolomic analysis provides strong support for the mechanistic study of 
insulin secretion. 
7.2 Conclusion 
Our studies clearly showed that a feasible GC-MS untargeted metabolomics strategy, from sample 
preparation to data interpretation, was established and its application can successfully convert the 
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knowledge discovery method from hypothesis-dependent to data-driven strategy. In this dissertation, 
untargeted metabolomics has been applied to studies of GSIS, the mechanism of biphasic insulin 
secretion and TDEs, as well as the role of iron-responsive and alpha-ketoglutarate dependent 
hydroxylation in regulation of insulin secretion.  
In addition to glycolysis, the PPP, sorbitol-aldose reductase pathway as well as aspartate are strongly 
suggested to be relevant to GSIS. For characterization of kinetics insulin secretion, alpha-
ketoglutarate, succinate and hydroxyproline were revealed to be the metabolites strongly associated 
with the second phase of biphasic insulin secretion. Study of TDEs by metabolomics shows that TDI 
effect is mainly regulated by redox state in pancreatic beta cells, since it is correlated to the decreased 
DHAP: alpha-GP ratio probably as a result of the diminished malate-aspartate shuttle activity, and the 
lowered lactate output in beta cells.  On the other hand, TDP is probably coupled with succinate-
regulated pro-insulin biosynthesis. Finally, alpha-ketoglutarate dependent hydroxylation was found to 
be a master regulation mechanism controlling glucose metabolism, a finding which, if true, provides a 
positive feedback loop for GSIS in pancreatic beta cells. 
7.3 Future outlook 
Despite the successful application of untargeted metabolomics in our study, fully comprehensive 
metabolomics requires improvements in both sample preparation and metabolite measurement. Truly 
unbiased sample preparation should include pre-fractionation and selective enrichment for the 
specific chemical properties of different classes of metabolites to facilitate the detection and analysis 
of the structurally diverse metabolites, even though it is time-consuming. In terms of metabolite 
determination, both GC and LC are highly recommended to cover the whole endogenous metabolome 
with a wide range chemical nature. It will be exceedingly helpful if a LC-MS/MS spectral library can 
be established. 
PCA, PLS, and OPLS are just basic algorithms for two-way X–Y data matrices, the modification of 
which is highly recommended. Evolvement of MVA basic algorithms leads to the development of 
quadratic PLS [462], batch-wise PLS (and PCA) [463], hierarchical PLS (and PCA) [289, 452-456], 
which are believed to have even greater promise because they can extend MVA to non-linear 
regression for multi-way data matrices.  
As shown by our data, alpha-ketoglutarate plays an important role in coupling glucose metabolism 
with insulin secretion probably by hydroxylation, which could happen to all enzymes regulating 
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glucose metabolism or to a master protein controlling glucose metabolic pathway. No matter which 
protein is the substrate of hydroxylation, alpha-ketoglutarate dependent hydroxylation provides a 
positive feedback mechanism for glucose-stimulated insulin secretion, since alpha-ketoglutarte itself 
is a glucose-carbon derived molecule generated in mitochondria. So, separation of metabolites 
contained in different cellular compartments, such as separation of metabolites in cytoplasm from 
mitochondria, is expected to be included in the sample preparation process for future studies. As 
glucose metabolism is clearly affected by EDHB, the next question to be answered is which enzyme 
exactly is the substrate for hydroxylation.    
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